Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2018 | Apr. 27, 2018 | |
Document Information [Line Items] | ||
Trading Symbol | ALGN | |
Entity Registrant Name | ALIGN TECHNOLOGY INC | |
Entity Central Index Key | 1,097,149 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Large Accelerated Filer | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2018 | |
Document Fiscal Year Focus | 2,018 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false | |
Entity Common Stock, Shares Outstanding | 80,149,641 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Income Statement [Abstract] | ||
Net revenues | $ 436,924 | $ 310,341 |
Cost of net revenues | 109,516 | 74,716 |
Gross profit | 327,408 | 235,625 |
Operating expenses: | ||
Selling, general and administrative | 199,625 | 151,148 |
Research and development | 29,591 | 22,804 |
Total operating expenses | 229,216 | 173,952 |
Income from operations | 98,192 | 61,673 |
Interest income | 2,176 | 1,195 |
Other income (expense), net | 177 | 450 |
Net income before provision for (benefit from) income taxes and equity in losses of investee | 100,545 | 63,318 |
Provision for (benefit from) income taxes | 2,902 | (7,223) |
Equity in losses of investee, net of tax | 1,777 | 1,121 |
Net income | $ 95,866 | $ 69,420 |
Net income per share: | ||
Basic (in usd per share) | $ 1.20 | $ 0.87 |
Diluted (in usd per share) | $ 1.17 | $ 0.85 |
Shares used in computing net income per share: | ||
Basic (in shares) | 80,036 | 79,904 |
Diluted (in shares) | 81,628 | 81,534 |
CONDENSED CONSOLIDATED STATEME3
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Statement of Comprehensive Income [Abstract] | ||
Net income | $ 95,866 | $ 69,420 |
Net change in foreign currency translation adjustment | 1,042 | (459) |
Change in unrealized gains (losses) on investments, net of tax | (129) | 15 |
Other comprehensive income (loss) | 913 | (444) |
Comprehensive income | $ 96,779 | $ 68,976 |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Current assets: | ||
Cash and cash equivalents | $ 498,003 | $ 449,511 |
Marketable securities, short-term | 164,740 | 272,031 |
Accounts receivable, net of allowance for doubtful accounts of $2,735 and $5,814, respectively | 361,459 | 324,189 |
Inventories | 35,866 | 31,688 |
Prepaid expenses and other current assets | 108,708 | 80,948 |
Total current assets | 1,168,776 | 1,158,367 |
Marketable securities, long-term | 10,212 | 39,948 |
Property, plant and equipment, net | 400,528 | 348,793 |
Equity method investments | 52,829 | 54,606 |
Goodwill and intangible assets, net | 87,629 | 89,068 |
Deferred tax assets | 45,524 | 49,334 |
Other assets | 17,233 | 43,893 |
Total assets | 1,782,731 | 1,784,009 |
Current liabilities: | ||
Accounts payable | 41,881 | 36,776 |
Accrued liabilities | 180,093 | 195,562 |
Deferred revenues | 296,011 | 267,713 |
Total current liabilities | 517,985 | 500,051 |
Income tax payable | 119,349 | 114,091 |
Other long-term liabilities | 17,937 | 15,579 |
Total liabilities | 655,271 | 629,721 |
Commitments and contingencies (Notes 8 and 9) | ||
Stockholders' equity: | ||
Preferred stock, $0.0001 par value (5,000 shares authorized; none issued) | 0 | 0 |
Common stock, $0.0001 par value (200,000 shares authorized; 80,144 and 80,040 issued and outstanding, respectively) | 8 | 8 |
Additional paid-in capital | 858,632 | 886,435 |
Accumulated other comprehensive income (loss), net | 1,484 | 571 |
Retained earnings | 267,336 | 267,274 |
Total stockholders’ equity | 1,127,460 | 1,154,288 |
Total liabilities and stockholders’ equity | $ 1,782,731 | $ 1,784,009 |
CONDENSED CONSOLIDATED BALANCE5
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) shares in Thousands, $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Accounts receivable, allowance for doubtful accounts and returns | $ 2,735 | $ 5,814 |
Preferred stock, par value (in usd per share) | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized | 5,000 | 5,000 |
Preferred stock, shares issued | 0 | 0 |
Common stock, par value (in usd per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 200,000 | 200,000 |
Common stock, shares issued | 80,144 | 80,040 |
Common stock, shares outstanding | 80,144 | 80,040 |
CONDENSED CONSOLIDATED STATEME6
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net income | $ 95,866 | $ 69,420 |
Adjustments to reconcile net income to net cash provided by operating activities: | ||
Deferred taxes | 4,069 | 7,789 |
Depreciation and amortization | 11,434 | 7,867 |
Stock-based compensation | 15,830 | 14,812 |
Equity in losses of investee | 1,777 | 1,121 |
Other non-cash operating activities | 474 | 2,079 |
Changes in assets and liabilities, net of effects of acquisitions: | ||
Accounts receivable | (36,026) | (24,525) |
Inventories | (4,002) | (7,923) |
Prepaid expenses and other assets | (15,873) | (527) |
Accounts payable | 5,599 | 5,522 |
Accrued and other long-term liabilities | (35,466) | (40,891) |
Long-term income tax payable | 5,259 | 1,189 |
Deferred revenues | 28,391 | 11,688 |
Net cash provided by operating activities | 77,332 | 47,621 |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||
Acquisitions, net of cash acquired | 0 | (8,953) |
Purchase of property, plant and equipment | (57,578) | (59,569) |
Purchase of marketable securities | 0 | (169,777) |
Proceeds from maturities of marketable securities | 126,825 | 87,003 |
Proceeds from sales of marketable securities | 9,560 | 11,684 |
Loan advances to equity investee | 0 | (8,000) |
Loan repayment from equity investee | 30,000 | 0 |
Other investing activities | 462 | (850) |
Net cash provided by (used in) investing activities | 109,269 | (148,462) |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Proceeds from issuance of common stock | 8,020 | 7,288 |
Common stock repurchases | (100,000) | (3,793) |
Employees’ taxes paid upon the vesting of restricted stock units | (47,842) | (36,496) |
Net cash used in financing activities | (139,822) | (33,001) |
Effect of foreign exchange rate changes on cash and cash equivalents, and restricted cash | 1,715 | 2,430 |
Net increase (decrease) in cash, cash equivalents, and restricted cash | 48,494 | (131,412) |
Cash, cash equivalents, and restricted cash at beginning of the period | 450,125 | 393,019 |
Cash, cash equivalents, and restricted cash at end of the period | 498,619 | 261,607 |
SUPPLEMENTAL CASH FLOW INFORMATION: | ||
Accounts payable or accrued liabilities related to property, plant and equipment | $ 18,739 | $ 7,662 |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2018 | |
Notes To Financial Statements [Abstract] | |
Summary of Significant Accounting Policies | Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared by Align Technology, Inc. (“we”, “our”, or “Align”) in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and contain all adjustments, including normal recurring adjustments, necessary to state fairly our results of operations for the three months ended March 31, 2018 and 2017 , our comprehensive income for the three months ended March 31, 2018 and 2017 , our financial position as of March 31, 2018 and our cash flows for the three months ended March 31, 2018 and 2017 . The Condensed Consolidated Balance Sheet as of December 31, 2017 was derived from the December 31, 2017 audited financial statements and have been recast to reflect the adoption of accounting standards as described below. It does not include all disclosures required by accounting principles generally accepted in the United States of America (“U.S.”). During the first quarter of fiscal year 2018, we adopted the Accounting Standards Codification (“ASC”) 606, “ Revenues from Contracts with Customers, ” using the full retrospective method and Accounting Standards Update (“ASU”) 2016-18, “Statement of Cash Flows - Restricted Cash,” on a retrospective basis. Condensed Consolidated Balance Sheet as of December 31, 2017 and Condensed Consolidated Statement of Cash Flow for the three months ended March 31, 2017 have been recast to comply with the adoption of these standards. The results of operations for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018 or any other future period, and we make no representations related thereto. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Quantitative and Qualitative Disclosures About Market Risk” and the Consolidated Financial Statements and notes thereto included in Items 7, 7A and 8, respectively, in our Annual Report on Form 10-K for the year ended December 31, 2017 . Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the U.S. requires our management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. On an ongoing basis, we evaluate our estimates, including those related to the fair values of financial instruments, long-lived assets and goodwill, equity method investments, useful lives of intangible assets and property and equipment, revenue recognition, stock-based compensation, income taxes and contingent liabilities, among others. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Significant Accounting Policies Our significant accounting policies are described in Note 1 “Summary of Significant Accounting Policies” of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K. Significant changes to the Revenue Recognition policy as a result of ASC 606 adoption are discussed below: Revenue Recognition Our revenues are derived primarily from the sale of aligners, scanners, and services from our Clear Aligner and Scanner segments. We enter into sales contracts that may consist of multiple distinct performance obligations where certain performance obligations of the sales contract are not delivered in one reporting period. We measure and allocate revenue according to Accounting Standards Codification (“ASC”) 606-10, “ Revenues from Contracts with Customers ”. We identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation. Clear Aligner We enter into contracts (“treatment plan(s)”) that involve multiple future performance obligations. Invisalign Full, Invisalign Teen, and Invisalign Assist products include optional additional aligners at no charge for a period of up to five years after initial shipment and Invisalign Go includes optional additional aligners at no charge for a period of up to two years after initial shipment. Invisalign Teen also includes up to six optional replacement aligners in the price of the product and may be ordered by the dental professional any time throughout treatment. Invisalign Lite includes one optional case refinement in the price of the product. Case refinement is a finishing tool used to adjust a patient’s teeth to the desired final position and may be elected by the dental professional at any time during treatment; however, it is generally ordered in the last stages of orthodontic treatment. We determined that our treatment plans comprise the following performance obligations that also represent distinct deliverables: initial aligners, additional aligners, case refinement, and replacement aligners. The Company elected to take the practical expedient to consider shipping and handling costs as activities to fulfill the performance obligation. We allocate revenue for each treatment plan based on each unit’s SSP and recognize the revenue over the manufacturing period, typically 1-3 days, as the aligners do not have an alternative use and we have enforceable rights to payment. As we collect most consideration upfront, we considered whether a significant financing component exists. However, as the delivery of the performance obligations are at the customer’s discretion, we concluded that no significant financing component exists. Scanners We sell intraoral scanners and CAD/CAM services through both our direct sales force and distribution partners. The intraoral scanner sales price includes one year of warranty and unlimited scanning services. The customer may, for additional fees, also select extended warranty and unlimited scanning services for periods beyond the initial year. When intraoral scanners are sold with an unlimited scanning service agreement and/or extended warranty, we allocate revenue based on each element’s SSP. We estimate the SSP of each element, taking into consideration historical prices as well as our discounting strategies. Revenue is then recognized over time as the monthly services are rendered and upon shipment for the scanner, as that is when we deem the customer to have obtained control. Warranties For both Clear Aligner and iTero scanner segments, the Company offers an assurance warranty, which provides the customer assurance that the product will function as the parties intended because it complies with agreed-upon specifications, and thus is not treated as a separate performance obligation and will continue to be accrued in accordance with the FASB guidance on guarantees. Volume Discounts In certain situations, we offer promotions in which the discount will increase depending upon the volume purchased over time. We concluded that in these situations, the promotions can represent either variable consideration or options, depending upon the specifics of the promotion. In the event the promotion contains an option, the option is considered a material right and therefore, included in the accounting for the initial arrangement. We estimate the average anticipated discount over the lifetime of the promotion or contract, and apply that discount to each unit as it is sold. On a quarterly basis, we review our estimates and if needed, updates are made and changes are applied prospectively. Costs to Obtain a Contract We offer a variety of commission plans to our salesforce; each plan has multiple components. To match the costs to obtain a contract to the associated revenue, we evaluate the individual components and capitalize the eligible components, recognizing the costs over the treatment period. Unfulfilled Performance Obligations for Clear Aligners and Scanners The Company’s unfilled performance obligations as of March 31, 2018 and the estimated revenue expected to be recognized in the future related to these performance obligations are $309 million . This includes performance obligations from the Clear Aligner segment, primarily the shipment of additional aligners, which are fulfilled over 1-5 years, and performance obligations from the iTero scanner segment, primarily contracted deliveries of additional scanners and support, which are fulfilled over 1-5 years. The estimate includes both product and service unfulfilled performance obligations and the time range reflect our best estimate of when the Company will transfer control to the customer and may change based on customer usage patterns, timing of shipments, readiness of customers’ facilities for installation, and manufacturing availability. Contract Balances The timing of revenue recognition results in deferred revenues on the Condensed Consolidated Balance Sheet. We usually collect the entire treatment fee prior to all performance obligations being performed and payment terms vary from net 30 to net 90. Contract liabilities are recorded as deferred revenue balances, which are generated based upon timing of invoices and recognition patterns, not payments. If the revenue recognition exceeds the billing, the exceeded amount is considered unbilled receivable and a contract asset. Conversely, if the billing occurs prior to the revenue recognition, the amount is considered deferred revenue and a contract liability. Recent Accounting Pronouncements (i) New Accounting Updates Recently Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) released ASU 2014-9, “ Revenue from Contracts with Customers, ” (Topic 606) to supersede nearly all existing revenue recognition guidance under GAAP. The core principle of the standard is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for the goods or services. We adopted the guidance in the first quarter of fiscal year 2018 by applying the full retrospective method. We have completed the financial statement impact of adoption including, but not limited to, volume-based discount programs, sales commissions and the identification of performance obligations. The impact of adoption was primarily related to the Clear Aligner segment. Our disaggregation of revenue can be found in Note 14 “Segments and Geographical Information.” The Company elected to take the practical expedient to exclude from the transaction price all taxes assessed by a governmental authority. In preparation for adoption of the standard, we have reviewed and, where necessary, implemented additional key system functionalities and internal controls to enable the preparation of financial information. Prior periods have been retrospectively adjusted, and we recognized cumulative effect of adopting the guidance as an adjustment to our opening balance of retained earnings as of January 1, 2016. The adoption of ASU 2014-09 did not have a material impact on our Condensed Consolidated Statements of Operations, Condensed Consolidated Statements of Comprehensive Income or Condensed Consolidated Statements of Cash Flows for the historical periods presented in the Item 1 Financial Statements section. Consolidated balance sheet line items, which reflect the adoption of the ASU 2014-09 are as follows (in thousands): December 31, 2017 As Previously Reported Adjustment As Adjusted Asset Accounts: Accounts receivable, net $ 322,825 $ 1,364 $ 324,189 Deferred tax assets 50,059 (725 ) 49,334 Other assets 38,379 5,514 43,893 Liability and Stockholders’ Equity Accounts: Accrued liabilities $ 194,198 $ 1,364 $ 195,562 Deferred revenues 266,842 871 267,713 Retained earnings 263,356 3,918 267,274 In August 2016, the FASB issued ASU 2016-15, “Classification of Certain Cash Receipts and Cash Payments,” which clarifies the presentation and classification of certain cash receipts and cash payments in the statements of cash flows. The amendments are effective for fiscal years and interim periods within those years beginning after December 15, 2017. We adopted the standard in the first quarter of fiscal year 2018 on a retrospective basis which did not have an impact on our consolidated statements of cash flows. In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows - Restricted Cash,” which provides guidance to address the classification and presentation of changes in restricted cash in the statements of cash flows . The amendments are effective for fiscal years and interim periods within those years beginning after December 15, 2017 on a retrospective basis. We adopted the guidance in the first quarter of fiscal year 2018 on a retrospective basis and presented the changes in the total of cash, cash equivalents, and restricted cash in the consolidated statements of cash flows. Consolidated statement of cash flows line items, which reflect the adoption of the ASU 2016-18, are as follows (in thousands): March 31, 2017 As Previously Reported Adjustment As Adjusted Cash Flows from Investing Activities Other investing activities $ 2,314 $ (3,164 ) $ (850 ) Net cash provided by (used in) investing activities (145,298 ) (3,164 ) (148,462 ) Net increase (decrease) in cash, cash equivalent, and restricted cash (128,248 ) (3,164 ) (131,412 ) Cash, cash equivalents, and restricted cash at beginning of the period 389,275 3,744 393,019 Cash, cash equivalents, and restricted cash at end of the period $ 261,027 $ 580 $ 261,607 In May 2017, the FASB issued ASU 2017-09, “ Compensation — Stock Compensation (Topic 718): Scope of Modification Accounting,” to clarify when to account for a change to the terms or conditions of a share-based payment award as a modification. The amendments are effective for fiscal years and interim periods within those years beginning after December 15, 2017 on a prospective basis. We adopted the standard in the first quarter of fiscal year 2018 on a prospective basis which did not have an impact on our consolidated financial statements and related disclosures. (ii) Recent Accounting Updates Not Yet Effective In February 2016, the FASB issued ASU 2016-02, “ Leases ” (Topic 842) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The updated guidance is effective for annual periods beginning after December 15, 2018, including interim periods within those fiscal years. We plan to adopt the standard in the first quarter of fiscal year 2019 by electing practical expedients available in the standard. While we are currently evaluating the impact of the adoption of this guidance on our consolidated financial statements, we expect the adoption will have a material increase in assets and liabilities on our consolidated balance sheet. In June 2016, the FASB issued ASU 2016-13, “ Financial Instruments - Credit Losses ” (Topic 326) . The FASB issued this update to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. The amendments in this update replace the existing guidance of incurred loss impairment methodology with an approach that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The updated guidance is effective for annual periods beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption of the update is permitted in fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We are currently evaluating the impact of this guidance on our consolidated financial statements and related disclosures. In January 2017, the FASB issued ASU 2017-04, “Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,” to simplify the subsequent measurement of goodwill by eliminating step two from the goodwill impairment test. Under the amendments, an entity will recognize an impairment charge for the amount by which the carrying value exceeds the fair value. The amendments are effective for fiscal years and interim periods within those years beginning after December 15, 2019 on a prospective basis and early adoption is permitted. We are currently evaluating the impact of this guidance on our consolidated financial statements and related disclosures. In February 2018, the FASB issued ASU 2018-02, “Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income,” which gives entities the option to reclassify to retained earnings the tax effects resulting from the U.S. Tax Cuts and Jobs Act (the “TCJA”) related to items in accumulated other comprehensive income. The amendments are effective for fiscal years and interim periods within those years beginning after December 15, 2018 on a retrospective basis and early adoption is permitted. We are currently evaluating the impact of this guidance on our consolidated financial statements and related disclosures. |
Marketable Securities and Fair
Marketable Securities and Fair Value Measurements | 3 Months Ended |
Mar. 31, 2018 | |
Notes To Financial Statements [Abstract] | |
Marketable Securities and Fair Value Measurements | Marketable Securities and Fair Value Measurements As of March 31, 2018 and December 31, 2017, the estimated fair value of our short-term and long-term marketable securities, classified as available for sale, are as follows (in thousands): Short-term March 31, 2018 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Commercial paper $ 20,447 $ — $ (1 ) $ 20,446 Corporate bonds 106,583 1 (333 ) 106,251 U.S. government agency bonds 8,999 — (52 ) 8,947 U.S. government treasury bonds 28,146 — (51 ) 28,095 Certificates of deposit 1,001 — — 1,001 Total marketable securities, short-term $ 165,176 $ 1 $ (437 ) $ 164,740 Long-term March 31, 2018 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. government agency bonds $ 7,032 $ — $ (66 ) $ 6,966 Corporate bonds 3,265 1 (20 ) 3,246 Total marketable securities, long-term $ 10,297 $ 1 $ (86 ) $ 10,212 Short-term December 31, 2017 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Commercial paper $ 58,503 $ — $ (1 ) $ 58,502 Corporate bonds 145,728 3 (174 ) 145,557 U.S. government agency bonds 3,013 — (7 ) 3,006 U.S. government treasury bonds 60,650 — (70 ) 60,580 Certificates of deposit 4,386 — — 4,386 Total marketable securities, short-term $ 272,280 $ 3 $ (252 ) $ 272,031 Long-term December 31, 2017 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. government agency bonds $ 15,023 $ — $ (68 ) $ 14,955 Corporate bonds 25,067 2 (76 ) 24,993 Total marketable securities, long-term $ 40,090 $ 2 $ (144 ) $ 39,948 Cash equivalents are not included in the table above as the gross unrealized gains and losses are not material. We have no short-term or long-term investments that have been in a continuous material unrealized loss position for greater than twelve months as of March 31, 2018 and December 31, 2017. Amounts reclassified to earnings from accumulated other comprehensive income (loss), net related to unrealized gains or losses were not material for the three months ended March 31, 2018 and 2017. For the three months ended March 31, 2018 and 2017, realized gains or losses were not material. Our fixed-income securities investment portfolio consists of investments that have a maximum effective maturity of 40 months on any individual security. The securities that we invest in are generally deemed to be low risk based on their credit ratings from the major rating agencies. The longer the duration of these securities, the more susceptible they are to changes in market interest rates and bond yields. As interest rates increase, those securities purchased at a lower yield show a mark-to-market unrealized loss. The unrealized losses are due primarily to changes in credit spreads and interest rates. We expect to realize the full value of all these investments upon maturity or sale. The weighted average remaining duration of these securities was approximately five months and six months as of March 31, 2018 and December 31, 2017 , respectively. As the carrying value approximates the fair value for our short-term and long-term marketable securities shown in the tables above, the following table summarizes the fair value of our short-term and long-term marketable securities classified by maturity as of March 31, 2018 and December 31, 2017 (in thousands): March 31, 2018 December 31, 2017 One year or less $ 164,740 $ 272,031 Due in greater than one year 10,212 39,948 Total available for sale short-term and long-term marketable securities $ 174,952 $ 311,979 Fair Value Measurements We measure the fair value of financial assets as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. We use the GAAP fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value: Level 1 — Quoted (unadjusted) prices in active markets for identical assets or liabilities. Our Level 1 assets consist of money market funds and U.S. government treasury bonds. We did not hold any Level 1 liabilities as of March 31, 2018 and December 31, 2017. Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. Our Level 2 assets consist of commercial paper, corporate bonds, U.S. government agency bonds, certificates of deposit and our Israeli funds that are mainly invested in insurance policies. We obtain fair values for our Level 2 investments. Our custody bank and asset managers independently use professional pricing services to gather pricing data which may include quoted market prices for identical or comparable financial instruments, or inputs other than quoted prices that are observable either directly or indirectly, and we are ultimately responsible for these underlying estimates. We did not hold any Level 2 liabilities as of March 31, 2018 and December 31, 2017. Level 3 — Unobservable inputs to the valuation methodology that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques, as well as significant management judgment or estimation. Certain investments in private companies contain embedded derivatives, which do not require bifurcation as we elected to measure these investments at fair value. Our Level 3 assets consist of convertible short-term notes receivable. The following table summarizes the reconciliation of assets measured and recorded at fair value on a recurring basis using significant unobservable inputs Level 3 (in thousands): Notes Receivable Balance as of December 31, 2017 $ 4,476 Accrued interest receivable 25 Change in fair value recognized in earnings 358 Balance as of March 31, 2018 $ 4,859 Subsequent to March 31, 2018, in April 2018, the convertible notes receivable issued to a privately held company was converted into equity shares as a result of qualified financing secured by the company. We did not hold any Level 3 liabilities as of March 31, 2018 and December 31, 2017. The following tables summarize our financial assets measured at fair value on a recurring basis as of March 31, 2018 and December 31, 2017 (in thousands): Description Balance as of March 31, 2018 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Other Cash equivalents: Money market funds $ 255,373 $ 255,373 $ — $ — Short-term investments: Commercial paper 20,446 — 20,446 — Corporate bonds 106,251 — 106,251 — U.S. government agency bonds 8,947 — 8,947 — U.S. government treasury bonds 28,095 28,095 — — Certificates of deposit 1,001 — 1,001 — Long-term investments: U.S. government agency bonds 6,966 — 6,966 — Corporate bonds 3,246 — 3,246 — Prepaid expenses and other current assets: Israeli funds 3,114 — 3,114 — Short-term notes receivable 4,859 — — 4,859 $ 438,298 $ 283,468 $ 149,971 $ 4,859 Description Balance as of December 31, 2017 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Other Cash equivalents: Money market funds $ 253,155 $ 253,155 $ — $ — Commercial paper 7,246 — 7,246 — Corporate bonds 2,016 — 2,016 — Short-term investments: Commercial paper 58,502 — 58,502 — Corporate bonds 145,557 — 145,557 — U.S. government agency bonds 3,006 — 3,006 — U.S. government treasury bonds 60,580 60,580 — — Certificates of deposit 4,386 — 4,386 — Long-term investments: U.S. government agency bonds 14,955 — 14,955 — Corporate bonds 24,993 — 24,993 — Prepaid expenses and other current assets: Israeli funds 3,075 — 3,075 — Short-term notes receivable 4,476 — — 4,476 $ 581,947 $ 313,735 $ 263,736 $ 4,476 Derivative Financial Instruments In March 2018, we began entering into foreign currency forward contracts to minimize the short-term impact of foreign currency exchange rate fluctuations on certain trade and intercompany receivables and payables. These forward contracts are classified within level 2 of the fair value hierarchy. There was no net gain or loss from the settlement of foreign currency forward contracts during the three months ended March 31, 2018. As of March 31, 2018 , the fair value of foreign exchange forward contracts outstanding was not material. The following table presents the gross notional value of all our foreign exchange forward contracts outstanding as of March 31, 2018 (in thousands): March 31, 2018 Local Currency Amount Notional Contract Amount (USD) Euro €40,000 $ 49,244 British Pound £9,000 12,615 $ 61,859 |
Balance Sheet Components
Balance Sheet Components | 3 Months Ended |
Mar. 31, 2018 | |
Notes To Financial Statements [Abstract] | |
Balance Sheet Components | Balance Sheet Components Inventories Inventories consist of the following (in thousands): March 31, December 31, Raw materials $ 13,386 $ 12,721 Work in process 11,442 12,157 Finished goods 11,038 6,810 Total inventories $ 35,866 $ 31,688 Other Assets Other assets consist of the following (in thousands): March 31, December 31, Capitalized commissions $ 7,681 $ 5,515 Other long-term assets 5,831 4,821 Security deposits 3,721 3,557 Loan receivable — 30,000 Total other assets $ 17,233 $ 43,893 Accrued Liabilities Accrued liabilities consist of the following (in thousands): March 31, December 31, Accrued payroll and benefits $ 69,581 $ 103,004 Accrued expenses 32,458 27,318 Accrued income taxes 17,134 12,405 Accrued fixed assets 15,241 11,362 Accrued warranty 6,657 5,929 Accrued professional fees 6,562 6,316 Accrued sales tax and value added tax 5,340 5,503 Accrued sales rebate 5,121 11,209 Accrued sales return reserve 1 4,887 1,364 Other accrued liabilities 17,112 11,152 Total accrued liabilities $ 180,093 $ 195,562 1 December 31, 2017 balance has been reclassified from accounts receivable, net to reflect the adoption of ASU 2014-09 ( Refer to Note 1 “Summary of Significant Accounting Policies” of the Notes to Condensed Consolidated Financial Statements for more information). Warranty We regularly review the balance for accrued warranty and update based on historical warranty trends. Actual warranty costs incurred have not materially differed from those accrued; however, future actual warranty costs could differ from the estimated amounts. Warranty accrual as of March 31, 2018 and 2017 consists of the following activity (in thousands): Three Months Ended 2018 2017 Balance at beginning of period $ 5,929 $ 3,841 Charged to cost of revenues 2,359 1,822 Actual warranty expenditures (1,631 ) (1,362 ) Balance at end of period $ 6,657 $ 4,301 Deferred Revenues Deferred revenues consist of the following (in thousands): March 31, December 31, Deferred revenues - current $ 296,011 $ 267,713 Deferred revenues - long-term 1 6,171 4,588 1 Included in other long-term liabilities on our Condensed Consolidated Balance Sheets During the three months ended March 31, 2018 and March 31, 2017, the Company recognized revenue of $437 million and $310 million , respectively, of which $86 million and $51 million were included in the deferred revenues balance at December 31, 2017 and December 31, 2016, respectively. |
Equity Method Investments
Equity Method Investments | 3 Months Ended |
Mar. 31, 2018 | |
Equity Method Investments and Joint Ventures [Abstract] | |
Equity Method Investments | Equity Method Investments On July 25, 2016, we acquired a 17% equity interest, on a fully diluted basis, in SmileDirectClub, LLC (“SDC”) for $46.7 million . The investment is accounted for under an equity method investment and the investee, SDC, is considered a related party. The investment is reported in our Condensed Consolidated Balance Sheet under equity method investments, and we record our proportional share of SDC’s losses within equity in losses of investee, net of tax, in our Condensed Consolidated Statement of Operations. On July 24, 2017, we purchased an additional 2% equity interest in SDC for $12.8 million . As a result of this purchase, we hold a 19% equity interest in SDC on a fully diluted basis. As of March 31, 2018 and December 31, 2017, the balance of our equity method investments was $52.8 million and $54.6 million , respectively. Concurrently with the investment on July 25, 2016, we also entered into a supply agreement with SDC to manufacture clear aligners for SDC’s doctor-led, at-home program for simple teeth straightening. The term of the supply agreement expires on December 31, 2019. We commenced supplying aligners to SDC in October 2016. The sale of aligners to SDC and the income from the supply agreement are reported in our Clear Aligner business segment. We eliminate unrealized profit on outstanding intercompany transactions. As of March 31, 2018 and December 31, 2017, the balance of accounts receivable due from SDC was $8.1 million and $14.3 million , respectively. For the three months ended March 31, 2018 and 2017, net revenues recognized from SDC were $5.3 million and $0.6 million , respectively. On July 25, 2016, we entered into a Loan and Security Agreement (the “Loan Agreement”) with SDC and amended on July 24, 2017 where we agreed to provide SDC a loan of up to $30.0 million in one or more advances. On February 7, 2018, $30.0 million of outstanding loan advances and related accrued interest were repaid in full, and the Loan Agreement was terminate ( Refer to Note 8 “Legal Proceedings” of the Notes to Condensed Consolidated Financial Statements for SDC legal proceedings discussion). |
Business Combinations
Business Combinations | 3 Months Ended |
Mar. 31, 2018 | |
Business Combinations [Abstract] | |
Business Combinations | Business Combinations During the first quarter of 2017, we completed the acquisitions of certain of our distributors for the total cash consideration of approximately $9.5 million including cash acquired. We recorded $1.9 million of net tangible liabilities, $8.2 million of identifiable intangible assets and $3.2 million of goodwill. The goodwill is primarily related to the benefit we expect to obtain from direct sales as we believe that the transition from our distributor arrangements to a direct sales model will increase our net revenues in the region as we will experience higher average sales prices (“ASP”) compared to our discounted ASP under the distribution agreements. The goodwill is not deductible for tax purposes. Pro forma results of operations for these acquisitions have not been presented as they were not material to our results of operations, either individually or in aggregate, for the three months ended March 31, 2017. |
Goodwill and Long-lived Assets
Goodwill and Long-lived Assets | 3 Months Ended |
Mar. 31, 2018 | |
Notes To Financial Statements [Abstract] | |
Goodwill and Intangible Assets | Goodwill and Intangible Assets Goodwill The change in the carrying value of goodwill for the three months ended March 31, 2018 , all attributable to our Clear Aligner reporting unit, is as follows (in thousands): Total Balance as of December 31, 2017 $ 64,614 Adjustments 1 7 Balance as of March 31, 2018 $ 64,621 1 The adjustments to goodwill during the period were a result of foreign currency translation. During the fourth quarter of fiscal 2017, we performed the annual goodwill impairment testing and found no impairment as the fair value of our Clear Aligner reporting unit was significantly in excess of the carrying value. Intangible Long-Lived Assets Acquired intangible long-lived assets are being amortized as follows (in thousands): Weighted Average Amortization Period (in years) Gross Carrying Amount as of Accumulated Amortization Accumulated Impairment Loss Net Carrying Trademarks 15 $ 7,100 $ (1,803 ) $ (4,179 ) $ 1,118 Existing technology 13 12,600 (4,845 ) (4,328 ) 3,427 Customer relationships 11 33,500 (15,147 ) (10,751 ) 7,602 Reacquired rights 3 7,500 (1,914 ) — 5,586 Patents 8 6,796 (1,712 ) — 5,084 Other 2 618 (427 ) — 191 Total intangible assets $ 68,114 $ (25,848 ) $ (19,258 ) $ 23,008 Weighted Average Amortization Period (in years) Gross Carrying Amount as of December 31, 2017 Accumulated Amortization Accumulated Impairment Loss Net Carrying Value as of December 31, 2017 Trademarks 15 $ 7,100 $ (1,769 ) $ (4,179 ) $ 1,152 Existing technology 13 12,600 (4,704 ) (4,328 ) 3,568 Customer relationships 11 33,500 (14,681 ) (10,751 ) 8,068 Reacquired rights 3 7,500 (1,356 ) — 6,144 Patents 8 6,798 (1,504 ) — 5,294 Other 2 618 (390 ) — 228 Total intangible assets $ 68,116 $ (24,404 ) $ (19,258 ) $ 24,454 The total estimated annual future amortization expense for these acquired intangible assets as of March 31, 2018 is as follows (in thousands): Fiscal Year Ending December 31, Remainder of 2018 $ 4,843 2019 6,343 2020 3,882 2021 3,389 2022 2,116 Thereafter 2,435 Total $ 23,008 Amortization for the three months ended March 31, 2018 and 2017 was $1.4 million for both periods. |
Credit Facilities
Credit Facilities | 3 Months Ended |
Mar. 31, 2018 | |
Notes To Financial Statements [Abstract] | |
Credit Facilities | Credit Facilities On February 27, 2018, we entered into a new credit facility for a $200.0 million revolving line of credit, with a $50.0 million letter of credit sublimit, and a maturity date of February 27, 2021, replacing the existing credit facility which we had $50.0 million revolving line of credit with a $10.0 million letter of credit. The credit facility requires us to comply with specific financial conditions and performance requirements. The loans bear interest, at our option, at either a rate based on the reserve adjusted LIBOR for the applicable interest period or a base rate, in each case plus a margin. The base rate is the highest of the credit facility’s publicly announced prime rate, the federal funds rate plus 0.50% and one month LIBOR plus 1.0% . The margin ranges from 1.25% to 1.75% for LIBOR loans and 0.25% to 0.75% for base rate loans. Interest on the loans is payable quarterly in arrears with respect to base rate loans and at the end of an interest period (and at three month intervals if the interest period exceeds three months) in the case of LIBOR loans. Principal, together with accrued and unpaid interest, is due on the maturity date. As of March 31, 2018, we had no outstanding borrowings under this credit facility and were in compliance with the conditions and performance requirements. |
Legal Proceedings (Notes)
Legal Proceedings (Notes) | 3 Months Ended |
Mar. 31, 2018 | |
Legal Proceedings [Abstract] | |
Legal Proceedings | Legal Proceedings Patent Infringement Lawsuit On November 14, 2017, Align filed six patent infringement lawsuits asserting 26 patents against 3Shape A/S, a Danish corporation, and a related U.S. corporate entity, asserting that 3Shape’s Trios intraoral scanning system and Dental System software infringe Align patents. Align filed two Section 337 complaints with the U.S. International Trade Commission (ITC) alleging that 3Shape violates U.S. trade laws by selling for importation and importing its infringing Trios intraoral scanning system and Dental System software. Align’s ITC complaints seek cease and desist orders and exclusion orders prohibiting the importation of 3Shape’s Trios scanning system and Dental System software products into the U.S. Align also filed four separate complaints in the United States District Court for the District of Delaware alleging patent infringement by 3Shape’s Trios intraoral scanning system and Dental System software. All of these district court complaints seek monetary damages and injunctive relief against further infringement. SDC Dispute On April 5, 2018, SDC Financial LLC, SmileDirectClub LLC, and the Members of SDC Financial LLC other than Align (collectively, the "SDC Entities") initiated proceedings that seek, among other forms of relief, to preliminarily and permanently enjoin all activities related to the Invisalign store pilot project, require Align to close the existing Invisalign stores, prohibit Align from opening any additional stores, and allow the SDC Entities to exercise a right to repurchase all of Align's SDC Financial LLC membership interests for a purchase price equal to the current capital account balance. We dispute the allegations that we have breached our obligations to the SDC Entities, including the allegation that the SDC Entities are entitled to exercise a repurchase right and we will oppose and vigorously defend ourselves in the proceedings. This dispute does not impact Align’s existing supply agreement with SDC which remains in place through 2019 and includes a minimum volume commitment. We are currently unable to predict the outcome of this amended complaint and therefore cannot determine the likelihood of loss nor estimate a range of possible loss, if any. In addition, in the course of Align’s operations, Align is involved in a variety of claims, suits, investigations, and proceedings, including actions with respect to intellectual property claims, patent infringement claims, government investigations, labor and employment claims, breach of contract claims, tax, and other matters. Regardless of the outcome, these proceedings can have an adverse impact on us because of defense costs, diversion of management resources, and other factors. Although the results of complex legal proceedings are difficult to predict and Align’s view of these matters may change in the future as litigation and events related thereto unfold; Align currently does not believe that these matters, individually or in the aggregate, will materially affect Align’s financial position, results of operations or cash flows. |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2018 | |
Notes To Financial Statements [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Operating Leases As of March 31, 2018 , minimum future lease payments for non-cancelable operating leases are as follows (in thousands): Fiscal Year Ending December 31, Operating Leases Remainder of 2018 $ 13,508 2019 15,061 2020 11,056 2021 9,270 2022 7,107 Thereafter 10,537 Total minimum future lease payments $ 66,539 Sublease income is not material and excluded from the table above. Other Commitments On July 25, 2016, we entered into a Loan and Security Agreement (the “Loan Agreement”) with SmileDirectClub, LLC (“SDC”) and subsequently amended on July 24, 2017 to provide a loan of up to $30.0 million in one or more advances to SDC (the “Loan Facility”). On February 7, 2018, $30.0 million of outstanding advances and related accrued interest were repaid in full, and the Loan Agreement was terminated ( Refer to Note 4 “Equity Method Investments” of the Notes to Condensed Consolidated Financial Statements for more information on our investments in SDC). Off-Balance Sheet Arrangements As of March 31, 2018 , we had no material off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our consolidated financial condition, results of operations, liquidity, capital expenditures or capital resources other than certain items disclosed in Note 9 “Commitments and Contingencies” of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K. Indemnification Provisions In the normal course of business to facilitate transactions in our services and products, we indemnify certain parties: customers, vendors, lessors, and other parties with respect to certain matters, including, but not limited to, services to be provided by us and intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with our directors and our executive officers that will require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. Several of these agreements limit the time within which an indemnification claim can be made and the amount of the claim. It is not possible to make a reasonable estimate of the maximum potential amount under these indemnification agreements due to the unique facts and circumstances involved in each particular agreement. Additionally, we have a limited history of prior indemnification claims and the payments we have made under such agreements have not had a material adverse effect on our results of operations, cash flows or financial position. However, to the extent that valid indemnification claims arise in the future, future payments by us could be significant and could have a material adverse effect on our results of operations or cash flows in a particular period. As of March 31, 2018 , we did not have any material indemnification claims that were probable or reasonably possible. |
Stockholders' Equity
Stockholders' Equity | 3 Months Ended |
Mar. 31, 2018 | |
Notes To Financial Statements [Abstract] | |
Stockholders' Equity | Stockholders’ Equity Summary of Stock-Based Compensation Expense As of March 31, 2018 , the 2005 Incentive Plan (as amended) has a total reserve of 27,783,379 shares of which 6,302,917 shares are available for issuance. Stock-based compensation is based on the estimated fair value of awards, net of estimated forfeitures, and recognized over the requisite service period. Estimated forfeitures are based on historical experience at the time of grant and may be revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The stock-based compensation related to all of our stock-based awards and employee stock purchases for the three months ended March 31, 2018 and 2017 is as follows (in thousands): Three Months Ended 2018 2017 Cost of net revenues $ 881 $ 925 Selling, general and administrative 12,578 11,716 Research and development 2,371 2,171 Total stock-based compensation $ 15,830 $ 14,812 Stock Options We have not granted options since 2011 and all outstanding options were fully vested and associated stock-based compensation expenses was recognized as of December 31, 2015. Activity for the three months ended March 31, 2018 under the stock option plans is set forth below: Number of Shares Underlying Stock Options (in thousands) Weighted Average Exercise Price per Share Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2017 75 $ 11.36 Exercised (15 ) 11.65 Cancelled or expired — — Outstanding as of March 31, 2018 60 $ 11.28 0.81 $ 14,369 Vested at March 31, 2018 60 $ 11.28 0.81 $ 14,369 Exercisable at March 31, 2018 60 $ 11.28 0.81 $ 14,369 Restricted Stock Units (“RSUs”) The fair value of restricted stock units (“RSUs”) is based on our closing stock price on the date of grant. A summary for the three months ended March 31, 2018 is as follows: Shares Underlying RSUs (in thousands) Weighted Average Grant Date Fair Value Weighted Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Nonvested as of December 31, 2017 1,341 $ 82.30 Granted 193 254.22 Vested and released (439 ) 67.12 Forfeited (39 ) 103.23 Nonvested as of March 31, 2018 1,056 $ 119.34 1.61 $ 265,087 As of March 31, 2018 , we expect to recognize $105.2 million of total unamortized compensation cost, net of estimated forfeitures, related to RSUs over a weighted average period of 2.5 years. Market-performance Based Restricted Stock Units (“MSUs”) On an annual basis, we grant market-performance based restricted stock units (“MSUs”) to our executive officers. Each MSU represents the right to one share of Align’s common stock. The actual number of MSUs which will be eligible to vest will be based on the performance of Align’s stock price relative to the performance of the NASDAQ Composite Index over the vesting period, generally two to three years, up to 250% of the MSUs initially granted. The following table summarizes the MSU performance for the three months ended March 31, 2018 : Number of Shares Underlying MSUs (in thousands) Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Nonvested as of December 31, 2017 428 $ 78.53 Granted 110 221.18 Vested and released (146 ) 56.75 Forfeited — — Nonvested as of March 31, 2018 392 $ 126.58 1.27 $ 98,468 As of March 31, 2018 , we expect to recognize $28.6 million of total unamortized compensation cost, net of estimated forfeitures, related to MSUs over a weighted average period of 1.3 years. Employee Stock Purchase Plan (“ESPP”) In May 2010, our shareholders approved the 2010 Employee Stock Purchase Plan (the “2010 Purchase Plan”) which will continue until terminated by either the Board of Directors or its administrator. The maximum number of shares available for purchase under the 2010 Purchase Plan is 2,400,000 shares. As of March 31, 2018 , we have 647,363 shares available for future issuance. The fair value of the option component of the 2010 Purchase Plan shares was estimated at the grant date using the Black-Scholes option pricing model with the following weighted average assumptions: Three Months Ended 2018 2017 Expected term (in years) 1.3 1.2 Expected volatility 35.7 % 26.1 % Risk-free interest rate 1.9 % 0.9 % Expected dividends — — Weighted average fair value at grant date $ 78.38 $ 26.09 As of March 31, 2018 , there was $2.4 million of total unamortized compensation costs related to employee stock purchases which we expect to be recognized over a weighted average period of 0.7 year. |
Common Stock Repurchase
Common Stock Repurchase | 3 Months Ended |
Mar. 31, 2018 | |
Notes To Financial Statements [Abstract] | |
Common Stock Repurchase | Common Stock Repurchase April 2014 Repurchase Program In January 2017, we repurchased on the open market approximately 0.04 million shares of our common stock at an average price of $96.37 per share, including commission for an aggregate purchase price of approximately $3.8 million , completing the April 2014 Repurchase Program. April 2016 Repurchase Program On April 28, 2016, we announced that our Board of Directors had authorized a plan to repurchase up to $300.0 million of the Company’s stock (“April 2016 Repurchase Program”). In May 2017, we entered into an accelerated share repurchase agreement ("2017 ASR") to repurchase $50.0 million of our common stock. The 2017 ASR was completed in August 2017. We received a total of approximately 0.4 million shares for an average share price of $146.48 . In November 2017, we repurchased on the open market approximately 0.2 million shares of our common stock at an average price of $243.40 per share, including commissions, for an aggregate purchase price of approximately $50.0 million . In February 2018, we repurchased on the open market approximately 0.4 million shares of our common stock at an average price of $252.24 per share, including commission for an aggregate purchase price of approximately $100.0 million . As of March 31, 2018, we have $100.0 million remaining under the April 2016 Repurchase Plan. |
Accounting for Income Taxes
Accounting for Income Taxes | 3 Months Ended |
Mar. 31, 2018 | |
Accounting for Income Taxes | Accounting for Income Taxes Our provision for (benefit from) income taxes was $ 2.9 million and $ (7.2) million for the three months ended March 31, 2018 and 2017 , respectively, representing effective tax rates of 2.9% and (11.4)% , respectively. As a result of the enactment of the U.S. Tax Cuts and Jobs Act (the “TCJA”), the U.S. federal statutory tax rate decreased from 35% to 21% effective January 1, 2018. Our effective tax rate differs from the statutory federal income tax rate of 21% and 35% for the three months ended March 31, 2018 and 2017 , respectively, mainly as a result of recognition of excess tax benefits related to stock-based compensation and certain foreign earnings, primarily from the Netherlands and Costa Rica, being taxed at lower tax rates. The increase in effective tax rate for the three months ended March 31, 2018 compared to the same period in 2017 is primarily attributable to the decrease in corporate tax rate from 35% to 21% pursuant to the enactment of the TCJA, which reduced the excess tax benefits related to stock-based compensation, and the benefits from foreign earnings being taxed at a lower tax rate. For the three months ended March 31, 2018 and 2017 , we recognized excess tax benefits of $23.3 million and $21.3 million , respectively, in our provision for (benefit from) income taxes. We exercise significant judgment in regards to estimates of future market growth, forecasted earnings and projected taxable income in determining the provision for income taxes and for purposes of assessing our ability to utilize any future benefit from deferred tax assets. We file U.S. federal, U.S. state, and non-U.S. income tax returns. Our major tax jurisdictions include U.S. federal, the State of California and the Netherlands. For U.S. federal and state tax returns, we are no longer subject to tax examinations for years before 2000 . With few exceptions, we are no longer subject to examination by foreign tax authorities for years before 2010 . Our total gross unrecognized tax benefits, excluding interest and penalties, was $50.3 million and $47.7 million as of March 31, 2018 and December 31, 2017 , respectively, all of which would impact our effective tax rate if recognized. Our total interest and penalties accrued as of March 31, 2018 was $3.3 million . We have elected to recognize interest and penalties related to unrecognized tax benefits as a component of income taxes. The timing and resolution of income tax examinations is uncertain, and the amounts ultimately paid, if any, upon resolution of issues raised by the taxing authorities may differ materially from the amounts accrued for each year. It is reasonably possible that the gross unrecognized tax benefits related to the years that are subject to examination could decrease, whether by payment, release, or a combination of both, in the next 12 months by $28 million , which would impact our effective tax rate. During the three months ended March 31, 2018 , we received notice that we are under examination by the Internal Revenue Service for the tax year of 2015. In June 2017, the Costa Rica Ministry of Foreign Trade, an agency of the Government of Costa Rica, granted an extension of certain income tax incentives for an additional twelve year period. Under these incentives, all of the income in Costa Rica is subject to a reduced tax rate. In order to receive the benefit of these incentives, we must hire specified numbers of employees and maintain certain minimum levels of fixed asset investment in Costa Rica. If we do not fulfill these conditions for any reason, our incentive could lapse and our income in Costa Rica would be subject to taxation at higher rates which could have a negative impact on our operating results. The Costa Rica corporate income tax rate that would apply, absent the incentives, is 30% for 2018 and 2017 . For the three months ended March 31, 2018 , the reduction in income taxes due to the reduced tax rate was minimal. As of December 31, 2017 , undistributed earnings of the Company totaled $606.5 million . We reassessed our capital needs and investment strategy with regard to the indefinite reinvestment of the undistributed earnings from certain of our foreign subsidiaries as a result of the one-time transition tax on cumulative foreign earnings under the TCJA. During the fourth quarter of 2017 , we determined that approximately $591.9 million of the total undistributed foreign earnings are no longer considered to be indefinitely reinvested outside the U.S. As a result, in the fourth quarter of 2017, we have recorded a deferred tax liability of approximately $3.3 million , which represents the provisional amount of U.S. state income taxes that would be due in the event these foreign earnings are distributed. The remaining amount of undistributed foreign earnings of approximately $14.7 million continues to be indefinitely reinvested in our international operations. Since U.S. federal income tax has already been provided under the provisions of the TCJA, the additional tax impact of the distribution of such foreign earnings to the U.S. parent would be limited to U.S. state income and withholding taxes and is not significant. As of December 31, 2017, we recorded a provisional tax charge of $84.3 million related to the one-time transition tax liability and other tax impact of the TJCA. In the first quarter of 2018, we recorded an additional provisional tax charge of $2.4 million , primarily resulting from further analysis of our cumulative foreign earnings balances affecting the transition tax liability. As we complete our analysis of the TJCA, we may make further adjustments to the provisional amounts, which may impact our provision for income taxes in the period in which the adjustments are made. The TCJA subjects a U.S. shareholder to tax on global intangible low-taxed income (“GILTI”) earned by certain foreign subsidiaries. The FASB Staff Q&A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. Given the complexity of the GILTI provisions, we are still evaluating the effects of the GILTI provisions and have not yet determined our accounting policy. As of March 31, 2018, as we are still evaluating the GILTI provisions and our analysis of future taxable income that is subject to GILTI, we have included GILTI related to current-year operations only in our estimated annual effective tax rate and have not provided additional GILTI on deferred items. |
Net Income Per Share
Net Income Per Share | 3 Months Ended |
Mar. 31, 2018 | |
Net Income Per Share | Net Income per Share Basic net income per share is computed using the weighted average number of shares of common stock outstanding during the period. Diluted net income per share is computed using the weighted average number of shares of common stock, adjusted for any dilutive effect of potential common stock. Potential common stock, computed using the treasury stock method, includes RSU, MSU, stock options and our ESPP. The following table sets forth the computation of basic and diluted net income per share attributable to common stock (in thousands, except per share amounts): Three Months Ended 2018 2017 Numerator: Net income $ 95,866 $ 69,420 Denominator: Weighted-average common shares outstanding, basic 80,036 79,904 Dilutive effect of potential common stock 1,592 1,630 Total shares, diluted 81,628 81,534 Net income per share, basic $ 1.20 $ 0.87 Net income per share, diluted $ 1.17 $ 0.85 For the three months ended March 31, 2018 and 2017, potentially anti-dilutive shares excluded from diluted net income per share related to RSUs, MSUs, stock options and ESPP were not material. |
Segments and Geographical Infor
Segments and Geographical Information | 3 Months Ended |
Mar. 31, 2018 | |
Notes To Financial Statements [Abstract] | |
Segments and Geographical Information | Segments and Geographical Information Segment Information Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (“CODM”), or decision-making group, in deciding how to allocate resources and in assessing performance. Our CODM is our Chief Executive Officer. We report segment information based on the management approach. The management approach designates the internal reporting used by CODM for decision making and performance assessment as the basis for determining our reportable segments. The performance measures of our reportable segments include net revenues, gross profit and income from operations. Income from operations for each segment includes all geographic revenues, related cost of net revenues and operating expenses directly attributable to the segment. Certain operating expenses are attributable to operating segments and each allocation is measured differently based on the specific facts and circumstances of the costs being allocated. Costs not specifically allocated to segment income from operations include various corporate expenses such as stock-based compensation and costs related to IT, facilities, human resources, accounting and finance, legal and regulatory, and other separately managed general and administrative costs outside the operating segments. We group our operations into two reportable segments: Clear Aligner segment and Scanner segment. • Our Clear Aligner segment consists of Comprehensive Products, Non-Comprehensive Products and Non-Case revenues as defined below: • Comprehensive Products include our Invisalign Full, Teen and Assist products. • Non-Comprehensive Products include our Invisalign Express, Invisalign Lite, Invisalign i7 and Invisalign Go products in addition to revenues from the sale of aligners to SmileDirectClub (“SDC”) under our supply agreement. • Non-Case includes our Vivera retainers along with our training and ancillary products for treating malocclusion. • Our Scanner segment consists of intraoral scanning systems and additional services available with the intraoral scanners that provide digital alternatives to the traditional cast models. This segment includes our iTero scanner and OrthoCAD services. We eliminate unrealized profit on outstanding intercompany transactions. These reportable operating segments are based on how our CODM views and evaluates our operations as well as allocation of resources. The following information relates to these segments (in thousands): Three Months Ended Net revenues 2018 2017 Clear Aligner $ 385,505 $ 282,399 Scanner 51,419 27,942 Total net revenues $ 436,924 $ 310,341 Gross profit Clear Aligner $ 296,976 $ 219,947 Scanner 30,432 15,678 Total gross profit $ 327,408 $ 235,625 Income from operations Clear Aligner $ 161,454 $ 114,734 Scanner 16,082 6,004 Unallocated corporate expenses (79,344 ) (59,065 ) Total income from operations $ 98,192 $ 61,673 Depreciation and amortization Clear Aligner $ 6,384 $ 4,363 Scanner 1,104 1,037 Unallocated corporate expenses 3,946 2,467 Total depreciation and amortization $ 11,434 $ 7,867 The following table reconciles total segment income from operations in the table above to net income before provision for (benefit from) income taxes and equity losses of investee, net of tax (in thousands): Three Months Ended 2018 2017 Total segment income from operations $ 177,536 $ 120,738 Unallocated corporate expenses (79,344 ) (59,065 ) Total income from operations 98,192 61,673 Interest income 2,176 1,195 Other income (expense), net 177 450 Net income before provision for (benefit from) income taxes and equity in losses of investee $ 100,545 $ 63,318 Geographical Information Net revenues are presented below by geographic area (in thousands): Three Months Ended 2018 2017 Net revenues 1 : United States $ 237,103 $ 183,273 The Netherlands 139,531 99,799 Other International 60,290 27,269 Total net revenues $ 436,924 $ 310,341 1 Net revenues are attributed to countries based on location of where revenue is recognized. Tangible long-lived assets are presented below by geographic area (in thousands): March 31, December 31, 2017 Long-lived assets 1 : The Netherlands $ 164,165 $ 143,673 United States 126,983 128,171 Costa Rica 48,470 30,738 Mexico 30,215 25,090 China 12,258 5,480 Other International 18,437 15,641 Total long-lived assets $ 400,528 $ 348,793 1 Long-lived assets are attributed to countries based on entity that owns the assets. |
Summary of Significant Accoun21
Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2018 | |
Notes To Financial Statements [Abstract] | |
Basis of presentation | Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared by Align Technology, Inc. (“we”, “our”, or “Align”) in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and contain all adjustments, including normal recurring adjustments, necessary to state fairly our results of operations for the three months ended March 31, 2018 and 2017 , our comprehensive income for the three months ended March 31, 2018 and 2017 , our financial position as of March 31, 2018 and our cash flows for the three months ended March 31, 2018 and 2017 . The Condensed Consolidated Balance Sheet as of December 31, 2017 was derived from the December 31, 2017 audited financial statements and have been recast to reflect the adoption of accounting standards as described below. It does not include all disclosures required by accounting principles generally accepted in the United States of America (“U.S.”). During the first quarter of fiscal year 2018, we adopted the Accounting Standards Codification (“ASC”) 606, “ Revenues from Contracts with Customers, ” using the full retrospective method and Accounting Standards Update (“ASU”) 2016-18, “Statement of Cash Flows - Restricted Cash,” on a retrospective basis. Condensed Consolidated Balance Sheet as of December 31, 2017 and Condensed Consolidated Statement of Cash Flow for the three months ended March 31, 2017 have been recast to comply with the adoption of these standards. The results of operations for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018 or any other future period, and we make no representations related thereto. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Quantitative and Qualitative Disclosures About Market Risk” and the Consolidated Financial Statements and notes thereto included in Items 7, 7A and 8, respectively, in our Annual Report on Form 10-K for the year ended December 31, 2017 . |
Use of estimates | Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the U.S. requires our management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. On an ongoing basis, we evaluate our estimates, including those related to the fair values of financial instruments, long-lived assets and goodwill, equity method investments, useful lives of intangible assets and property and equipment, revenue recognition, stock-based compensation, income taxes and contingent liabilities, among others. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. |
Revenue Recognition | Revenue Recognition Our revenues are derived primarily from the sale of aligners, scanners, and services from our Clear Aligner and Scanner segments. We enter into sales contracts that may consist of multiple distinct performance obligations where certain performance obligations of the sales contract are not delivered in one reporting period. We measure and allocate revenue according to Accounting Standards Codification (“ASC”) 606-10, “ Revenues from Contracts with Customers ”. We identify a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on our financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation. Clear Aligner We enter into contracts (“treatment plan(s)”) that involve multiple future performance obligations. Invisalign Full, Invisalign Teen, and Invisalign Assist products include optional additional aligners at no charge for a period of up to five years after initial shipment and Invisalign Go includes optional additional aligners at no charge for a period of up to two years after initial shipment. Invisalign Teen also includes up to six optional replacement aligners in the price of the product and may be ordered by the dental professional any time throughout treatment. Invisalign Lite includes one optional case refinement in the price of the product. Case refinement is a finishing tool used to adjust a patient’s teeth to the desired final position and may be elected by the dental professional at any time during treatment; however, it is generally ordered in the last stages of orthodontic treatment. We determined that our treatment plans comprise the following performance obligations that also represent distinct deliverables: initial aligners, additional aligners, case refinement, and replacement aligners. The Company elected to take the practical expedient to consider shipping and handling costs as activities to fulfill the performance obligation. We allocate revenue for each treatment plan based on each unit’s SSP and recognize the revenue over the manufacturing period, typically 1-3 days, as the aligners do not have an alternative use and we have enforceable rights to payment. As we collect most consideration upfront, we considered whether a significant financing component exists. However, as the delivery of the performance obligations are at the customer’s discretion, we concluded that no significant financing component exists. Scanners We sell intraoral scanners and CAD/CAM services through both our direct sales force and distribution partners. The intraoral scanner sales price includes one year of warranty and unlimited scanning services. The customer may, for additional fees, also select extended warranty and unlimited scanning services for periods beyond the initial year. When intraoral scanners are sold with an unlimited scanning service agreement and/or extended warranty, we allocate revenue based on each element’s SSP. We estimate the SSP of each element, taking into consideration historical prices as well as our discounting strategies. Revenue is then recognized over time as the monthly services are rendered and upon shipment for the scanner, as that is when we deem the customer to have obtained control. Warranties For both Clear Aligner and iTero scanner segments, the Company offers an assurance warranty, which provides the customer assurance that the product will function as the parties intended because it complies with agreed-upon specifications, and thus is not treated as a separate performance obligation and will continue to be accrued in accordance with the FASB guidance on guarantees. Volume Discounts In certain situations, we offer promotions in which the discount will increase depending upon the volume purchased over time. We concluded that in these situations, the promotions can represent either variable consideration or options, depending upon the specifics of the promotion. In the event the promotion contains an option, the option is considered a material right and therefore, included in the accounting for the initial arrangement. We estimate the average anticipated discount over the lifetime of the promotion or contract, and apply that discount to each unit as it is sold. On a quarterly basis, we review our estimates and if needed, updates are made and changes are applied prospectively. Costs to Obtain a Contract We offer a variety of commission plans to our salesforce; each plan has multiple components. To match the costs to obtain a contract to the associated revenue, we evaluate the individual components and capitalize the eligible components, recognizing the costs over the treatment period. Unfulfilled Performance Obligations for Clear Aligners and Scanners The Company’s unfilled performance obligations as of March 31, 2018 and the estimated revenue expected to be recognized in the future related to these performance obligations are $309 million . This includes performance obligations from the Clear Aligner segment, primarily the shipment of additional aligners, which are fulfilled over 1-5 years, and performance obligations from the iTero scanner segment, primarily contracted deliveries of additional scanners and support, which are fulfilled over 1-5 years. The estimate includes both product and service unfulfilled performance obligations and the time range reflect our best estimate of when the Company will transfer control to the customer and may change based on customer usage patterns, timing of shipments, readiness of customers’ facilities for installation, and manufacturing availability. Contract Balances The timing of revenue recognition results in deferred revenues on the Condensed Consolidated Balance Sheet. We usually collect the entire treatment fee prior to all performance obligations being performed and payment terms vary from net 30 to net 90. Contract liabilities are recorded as deferred revenue balances, which are generated based upon timing of invoices and recognition patterns, not payments. If the revenue recognition exceeds the billing, the exceeded amount is considered unbilled receivable and a contract asset. Conversely, if the billing occurs prior to the revenue recognition, the amount is considered deferred revenue and a contract liability. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements (i) New Accounting Updates Recently Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) released ASU 2014-9, “ Revenue from Contracts with Customers, ” (Topic 606) to supersede nearly all existing revenue recognition guidance under GAAP. The core principle of the standard is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for the goods or services. We adopted the guidance in the first quarter of fiscal year 2018 by applying the full retrospective method. We have completed the financial statement impact of adoption including, but not limited to, volume-based discount programs, sales commissions and the identification of performance obligations. The impact of adoption was primarily related to the Clear Aligner segment. Our disaggregation of revenue can be found in Note 14 “Segments and Geographical Information.” The Company elected to take the practical expedient to exclude from the transaction price all taxes assessed by a governmental authority. In preparation for adoption of the standard, we have reviewed and, where necessary, implemented additional key system functionalities and internal controls to enable the preparation of financial information. Prior periods have been retrospectively adjusted, and we recognized cumulative effect of adopting the guidance as an adjustment to our opening balance of retained earnings as of January 1, 2016. The adoption of ASU 2014-09 did not have a material impact on our Condensed Consolidated Statements of Operations, Condensed Consolidated Statements of Comprehensive Income or Condensed Consolidated Statements of Cash Flows for the historical periods presented in the Item 1 Financial Statements section. Consolidated balance sheet line items, which reflect the adoption of the ASU 2014-09 are as follows (in thousands): December 31, 2017 As Previously Reported Adjustment As Adjusted Asset Accounts: Accounts receivable, net $ 322,825 $ 1,364 $ 324,189 Deferred tax assets 50,059 (725 ) 49,334 Other assets 38,379 5,514 43,893 Liability and Stockholders’ Equity Accounts: Accrued liabilities $ 194,198 $ 1,364 $ 195,562 Deferred revenues 266,842 871 267,713 Retained earnings 263,356 3,918 267,274 In August 2016, the FASB issued ASU 2016-15, “Classification of Certain Cash Receipts and Cash Payments,” which clarifies the presentation and classification of certain cash receipts and cash payments in the statements of cash flows. The amendments are effective for fiscal years and interim periods within those years beginning after December 15, 2017. We adopted the standard in the first quarter of fiscal year 2018 on a retrospective basis which did not have an impact on our consolidated statements of cash flows. In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows - Restricted Cash,” which provides guidance to address the classification and presentation of changes in restricted cash in the statements of cash flows . The amendments are effective for fiscal years and interim periods within those years beginning after December 15, 2017 on a retrospective basis. We adopted the guidance in the first quarter of fiscal year 2018 on a retrospective basis and presented the changes in the total of cash, cash equivalents, and restricted cash in the consolidated statements of cash flows. Consolidated statement of cash flows line items, which reflect the adoption of the ASU 2016-18, are as follows (in thousands): March 31, 2017 As Previously Reported Adjustment As Adjusted Cash Flows from Investing Activities Other investing activities $ 2,314 $ (3,164 ) $ (850 ) Net cash provided by (used in) investing activities (145,298 ) (3,164 ) (148,462 ) Net increase (decrease) in cash, cash equivalent, and restricted cash (128,248 ) (3,164 ) (131,412 ) Cash, cash equivalents, and restricted cash at beginning of the period 389,275 3,744 393,019 Cash, cash equivalents, and restricted cash at end of the period $ 261,027 $ 580 $ 261,607 In May 2017, the FASB issued ASU 2017-09, “ Compensation — Stock Compensation (Topic 718): Scope of Modification Accounting,” to clarify when to account for a change to the terms or conditions of a share-based payment award as a modification. The amendments are effective for fiscal years and interim periods within those years beginning after December 15, 2017 on a prospective basis. We adopted the standard in the first quarter of fiscal year 2018 on a prospective basis which did not have an impact on our consolidated financial statements and related disclosures. (ii) Recent Accounting Updates Not Yet Effective In February 2016, the FASB issued ASU 2016-02, “ Leases ” (Topic 842) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The updated guidance is effective for annual periods beginning after December 15, 2018, including interim periods within those fiscal years. We plan to adopt the standard in the first quarter of fiscal year 2019 by electing practical expedients available in the standard. While we are currently evaluating the impact of the adoption of this guidance on our consolidated financial statements, we expect the adoption will have a material increase in assets and liabilities on our consolidated balance sheet. In June 2016, the FASB issued ASU 2016-13, “ Financial Instruments - Credit Losses ” (Topic 326) . The FASB issued this update to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. The amendments in this update replace the existing guidance of incurred loss impairment methodology with an approach that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The updated guidance is effective for annual periods beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption of the update is permitted in fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We are currently evaluating the impact of this guidance on our consolidated financial statements and related disclosures. In January 2017, the FASB issued ASU 2017-04, “Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,” to simplify the subsequent measurement of goodwill by eliminating step two from the goodwill impairment test. Under the amendments, an entity will recognize an impairment charge for the amount by which the carrying value exceeds the fair value. The amendments are effective for fiscal years and interim periods within those years beginning after December 15, 2019 on a prospective basis and early adoption is permitted. We are currently evaluating the impact of this guidance on our consolidated financial statements and related disclosures. In February 2018, the FASB issued ASU 2018-02, “Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income,” which gives entities the option to reclassify to retained earnings the tax effects resulting from the U.S. Tax Cuts and Jobs Act (the “TCJA”) related to items in accumulated other comprehensive income. The amendments are effective for fiscal years and interim periods within those years beginning after December 15, 2018 on a retrospective basis and early adoption is permitted. We are currently evaluating the impact of this guidance on our consolidated financial statements and related disclosures. |
Summary of Significant Accoun22
Summary of Significant Accounting Policies (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Notes To Financial Statements [Abstract] | |
Schedule of New Accounting Pronouncements and Changes in Accounting Principles | Consolidated statement of cash flows line items, which reflect the adoption of the ASU 2016-18, are as follows (in thousands): March 31, 2017 As Previously Reported Adjustment As Adjusted Cash Flows from Investing Activities Other investing activities $ 2,314 $ (3,164 ) $ (850 ) Net cash provided by (used in) investing activities (145,298 ) (3,164 ) (148,462 ) Net increase (decrease) in cash, cash equivalent, and restricted cash (128,248 ) (3,164 ) (131,412 ) Cash, cash equivalents, and restricted cash at beginning of the period 389,275 3,744 393,019 Cash, cash equivalents, and restricted cash at end of the period $ 261,027 $ 580 $ 261,607 Consolidated balance sheet line items, which reflect the adoption of the ASU 2014-09 are as follows (in thousands): December 31, 2017 As Previously Reported Adjustment As Adjusted Asset Accounts: Accounts receivable, net $ 322,825 $ 1,364 $ 324,189 Deferred tax assets 50,059 (725 ) 49,334 Other assets 38,379 5,514 43,893 Liability and Stockholders’ Equity Accounts: Accrued liabilities $ 194,198 $ 1,364 $ 195,562 Deferred revenues 266,842 871 267,713 Retained earnings 263,356 3,918 267,274 |
Marketable Securities and Fai23
Marketable Securities and Fair Value Measurements (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Notes To Financial Statements [Abstract] | |
Short-Term And Long-Term Marketable Securities | As of March 31, 2018 and December 31, 2017, the estimated fair value of our short-term and long-term marketable securities, classified as available for sale, are as follows (in thousands): Short-term March 31, 2018 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Commercial paper $ 20,447 $ — $ (1 ) $ 20,446 Corporate bonds 106,583 1 (333 ) 106,251 U.S. government agency bonds 8,999 — (52 ) 8,947 U.S. government treasury bonds 28,146 — (51 ) 28,095 Certificates of deposit 1,001 — — 1,001 Total marketable securities, short-term $ 165,176 $ 1 $ (437 ) $ 164,740 Long-term March 31, 2018 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. government agency bonds $ 7,032 $ — $ (66 ) $ 6,966 Corporate bonds 3,265 1 (20 ) 3,246 Total marketable securities, long-term $ 10,297 $ 1 $ (86 ) $ 10,212 Short-term December 31, 2017 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Commercial paper $ 58,503 $ — $ (1 ) $ 58,502 Corporate bonds 145,728 3 (174 ) 145,557 U.S. government agency bonds 3,013 — (7 ) 3,006 U.S. government treasury bonds 60,650 — (70 ) 60,580 Certificates of deposit 4,386 — — 4,386 Total marketable securities, short-term $ 272,280 $ 3 $ (252 ) $ 272,031 Long-term December 31, 2017 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. government agency bonds $ 15,023 $ — $ (68 ) $ 14,955 Corporate bonds 25,067 2 (76 ) 24,993 Total marketable securities, long-term $ 40,090 $ 2 $ (144 ) $ 39,948 |
Investments Classified by Contractual Maturity Date | As the carrying value approximates the fair value for our short-term and long-term marketable securities shown in the tables above, the following table summarizes the fair value of our short-term and long-term marketable securities classified by maturity as of March 31, 2018 and December 31, 2017 (in thousands): March 31, 2018 December 31, 2017 One year or less $ 164,740 $ 272,031 Due in greater than one year 10,212 39,948 Total available for sale short-term and long-term marketable securities $ 174,952 $ 311,979 |
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation | The following table summarizes the reconciliation of assets measured and recorded at fair value on a recurring basis using significant unobservable inputs Level 3 (in thousands): Notes Receivable Balance as of December 31, 2017 $ 4,476 Accrued interest receivable 25 Change in fair value recognized in earnings 358 Balance as of March 31, 2018 $ 4,859 |
Financial Assets Measured At Fair Value On Recurring Basis | The following tables summarize our financial assets measured at fair value on a recurring basis as of March 31, 2018 and December 31, 2017 (in thousands): Description Balance as of March 31, 2018 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Other Cash equivalents: Money market funds $ 255,373 $ 255,373 $ — $ — Short-term investments: Commercial paper 20,446 — 20,446 — Corporate bonds 106,251 — 106,251 — U.S. government agency bonds 8,947 — 8,947 — U.S. government treasury bonds 28,095 28,095 — — Certificates of deposit 1,001 — 1,001 — Long-term investments: U.S. government agency bonds 6,966 — 6,966 — Corporate bonds 3,246 — 3,246 — Prepaid expenses and other current assets: Israeli funds 3,114 — 3,114 — Short-term notes receivable 4,859 — — 4,859 $ 438,298 $ 283,468 $ 149,971 $ 4,859 Description Balance as of December 31, 2017 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Other Cash equivalents: Money market funds $ 253,155 $ 253,155 $ — $ — Commercial paper 7,246 — 7,246 — Corporate bonds 2,016 — 2,016 — Short-term investments: Commercial paper 58,502 — 58,502 — Corporate bonds 145,557 — 145,557 — U.S. government agency bonds 3,006 — 3,006 — U.S. government treasury bonds 60,580 60,580 — — Certificates of deposit 4,386 — 4,386 — Long-term investments: U.S. government agency bonds 14,955 — 14,955 — Corporate bonds 24,993 — 24,993 — Prepaid expenses and other current assets: Israeli funds 3,075 — 3,075 — Short-term notes receivable 4,476 — — 4,476 $ 581,947 $ 313,735 $ 263,736 $ 4,476 |
Notional value of derivative instruments | The following table presents the gross notional value of all our foreign exchange forward contracts outstanding as of March 31, 2018 (in thousands): March 31, 2018 Local Currency Amount Notional Contract Amount (USD) Euro €40,000 $ 49,244 British Pound £9,000 12,615 $ 61,859 |
Balance Sheet Components (Table
Balance Sheet Components (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Notes To Financial Statements [Abstract] | |
Schedule of Inventories | Inventories consist of the following (in thousands): March 31, December 31, Raw materials $ 13,386 $ 12,721 Work in process 11,442 12,157 Finished goods 11,038 6,810 Total inventories $ 35,866 $ 31,688 |
Schedule of Other Assets | Other assets consist of the following (in thousands): March 31, December 31, Capitalized commissions $ 7,681 $ 5,515 Other long-term assets 5,831 4,821 Security deposits 3,721 3,557 Loan receivable — 30,000 Total other assets $ 17,233 $ 43,893 |
Schedule of Accrued Liabilities | Accrued liabilities consist of the following (in thousands): March 31, December 31, Accrued payroll and benefits $ 69,581 $ 103,004 Accrued expenses 32,458 27,318 Accrued income taxes 17,134 12,405 Accrued fixed assets 15,241 11,362 Accrued warranty 6,657 5,929 Accrued professional fees 6,562 6,316 Accrued sales tax and value added tax 5,340 5,503 Accrued sales rebate 5,121 11,209 Accrued sales return reserve 1 4,887 1,364 Other accrued liabilities 17,112 11,152 Total accrued liabilities $ 180,093 $ 195,562 1 December 31, 2017 balance has been reclassified from accounts receivable, net to reflect the adoption of ASU 2014-09 ( Refer to Note 1 “Summary of Significant Accounting Policies” of the Notes to Condensed Consolidated Financial Statements for more information). |
Schedule of Warranty Accrual | Warranty accrual as of March 31, 2018 and 2017 consists of the following activity (in thousands): Three Months Ended 2018 2017 Balance at beginning of period $ 5,929 $ 3,841 Charged to cost of revenues 2,359 1,822 Actual warranty expenditures (1,631 ) (1,362 ) Balance at end of period $ 6,657 $ 4,301 |
Schedule of Deferred Revenues | Deferred revenues consist of the following (in thousands): March 31, December 31, Deferred revenues - current $ 296,011 $ 267,713 Deferred revenues - long-term 1 6,171 4,588 1 Included in other long-term liabilities on our Condensed Consolidated Balance Sheets |
Goodwill and Intangible Assets
Goodwill and Intangible Assets (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Notes To Financial Statements [Abstract] | |
Summary of Goodwill by Reportable Segment | The change in the carrying value of goodwill for the three months ended March 31, 2018 , all attributable to our Clear Aligner reporting unit, is as follows (in thousands): Total Balance as of December 31, 2017 $ 64,614 Adjustments 1 7 Balance as of March 31, 2018 $ 64,621 1 The adjustments to goodwill during the period were a result of foreign currency translation. |
Schedule of Amortized Intangible Assets | Acquired intangible long-lived assets are being amortized as follows (in thousands): Weighted Average Amortization Period (in years) Gross Carrying Amount as of Accumulated Amortization Accumulated Impairment Loss Net Carrying Trademarks 15 $ 7,100 $ (1,803 ) $ (4,179 ) $ 1,118 Existing technology 13 12,600 (4,845 ) (4,328 ) 3,427 Customer relationships 11 33,500 (15,147 ) (10,751 ) 7,602 Reacquired rights 3 7,500 (1,914 ) — 5,586 Patents 8 6,796 (1,712 ) — 5,084 Other 2 618 (427 ) — 191 Total intangible assets $ 68,114 $ (25,848 ) $ (19,258 ) $ 23,008 Weighted Average Amortization Period (in years) Gross Carrying Amount as of December 31, 2017 Accumulated Amortization Accumulated Impairment Loss Net Carrying Value as of December 31, 2017 Trademarks 15 $ 7,100 $ (1,769 ) $ (4,179 ) $ 1,152 Existing technology 13 12,600 (4,704 ) (4,328 ) 3,568 Customer relationships 11 33,500 (14,681 ) (10,751 ) 8,068 Reacquired rights 3 7,500 (1,356 ) — 6,144 Patents 8 6,798 (1,504 ) — 5,294 Other 2 618 (390 ) — 228 Total intangible assets $ 68,116 $ (24,404 ) $ (19,258 ) $ 24,454 |
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense | The total estimated annual future amortization expense for these acquired intangible assets as of March 31, 2018 is as follows (in thousands): Fiscal Year Ending December 31, Remainder of 2018 $ 4,843 2019 6,343 2020 3,882 2021 3,389 2022 2,116 Thereafter 2,435 Total $ 23,008 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Notes To Financial Statements [Abstract] | |
Schedule of Future Lease Payments | As of March 31, 2018 , minimum future lease payments for non-cancelable operating leases are as follows (in thousands): Fiscal Year Ending December 31, Operating Leases Remainder of 2018 $ 13,508 2019 15,061 2020 11,056 2021 9,270 2022 7,107 Thereafter 10,537 Total minimum future lease payments $ 66,539 |
Stockholders' Equity (Tables)
Stockholders' Equity (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Notes To Financial Statements [Abstract] | |
Stock-based Compensation Expense | The stock-based compensation related to all of our stock-based awards and employee stock purchases for the three months ended March 31, 2018 and 2017 is as follows (in thousands): Three Months Ended 2018 2017 Cost of net revenues $ 881 $ 925 Selling, general and administrative 12,578 11,716 Research and development 2,371 2,171 Total stock-based compensation $ 15,830 $ 14,812 |
Stock Option Activity | Activity for the three months ended March 31, 2018 under the stock option plans is set forth below: Number of Shares Underlying Stock Options (in thousands) Weighted Average Exercise Price per Share Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2017 75 $ 11.36 Exercised (15 ) 11.65 Cancelled or expired — — Outstanding as of March 31, 2018 60 $ 11.28 0.81 $ 14,369 Vested at March 31, 2018 60 $ 11.28 0.81 $ 14,369 Exercisable at March 31, 2018 60 $ 11.28 0.81 $ 14,369 |
Summary Of Restricted Stock Units | A summary for the three months ended March 31, 2018 is as follows: Shares Underlying RSUs (in thousands) Weighted Average Grant Date Fair Value Weighted Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Nonvested as of December 31, 2017 1,341 $ 82.30 Granted 193 254.22 Vested and released (439 ) 67.12 Forfeited (39 ) 103.23 Nonvested as of March 31, 2018 1,056 $ 119.34 1.61 $ 265,087 |
Summary Of Market-performance Based Restricted Stock Units | The following table summarizes the MSU performance for the three months ended March 31, 2018 : Number of Shares Underlying MSUs (in thousands) Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Nonvested as of December 31, 2017 428 $ 78.53 Granted 110 221.18 Vested and released (146 ) 56.75 Forfeited — — Nonvested as of March 31, 2018 392 $ 126.58 1.27 $ 98,468 |
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions | The fair value of the option component of the 2010 Purchase Plan shares was estimated at the grant date using the Black-Scholes option pricing model with the following weighted average assumptions: Three Months Ended 2018 2017 Expected term (in years) 1.3 1.2 Expected volatility 35.7 % 26.1 % Risk-free interest rate 1.9 % 0.9 % Expected dividends — — Weighted average fair value at grant date $ 78.38 $ 26.09 |
Net Income Per Share (Tables)
Net Income Per Share (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Schedule Of Earnings Per Share Basic And Diluted | The following table sets forth the computation of basic and diluted net income per share attributable to common stock (in thousands, except per share amounts): Three Months Ended 2018 2017 Numerator: Net income $ 95,866 $ 69,420 Denominator: Weighted-average common shares outstanding, basic 80,036 79,904 Dilutive effect of potential common stock 1,592 1,630 Total shares, diluted 81,628 81,534 Net income per share, basic $ 1.20 $ 0.87 Net income per share, diluted $ 1.17 $ 0.85 |
Segments and Geographical Inf29
Segments and Geographical Information (Tables) | 3 Months Ended |
Mar. 31, 2018 | |
Notes To Financial Statements [Abstract] | |
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas | These reportable operating segments are based on how our CODM views and evaluates our operations as well as allocation of resources. The following information relates to these segments (in thousands): Three Months Ended Net revenues 2018 2017 Clear Aligner $ 385,505 $ 282,399 Scanner 51,419 27,942 Total net revenues $ 436,924 $ 310,341 Gross profit Clear Aligner $ 296,976 $ 219,947 Scanner 30,432 15,678 Total gross profit $ 327,408 $ 235,625 Income from operations Clear Aligner $ 161,454 $ 114,734 Scanner 16,082 6,004 Unallocated corporate expenses (79,344 ) (59,065 ) Total income from operations $ 98,192 $ 61,673 Depreciation and amortization Clear Aligner $ 6,384 $ 4,363 Scanner 1,104 1,037 Unallocated corporate expenses 3,946 2,467 Total depreciation and amortization $ 11,434 $ 7,867 The following table reconciles total segment income from operations in the table above to net income before provision for (benefit from) income taxes and equity losses of investee, net of tax (in thousands): Three Months Ended 2018 2017 Total segment income from operations $ 177,536 $ 120,738 Unallocated corporate expenses (79,344 ) (59,065 ) Total income from operations 98,192 61,673 Interest income 2,176 1,195 Other income (expense), net 177 450 Net income before provision for (benefit from) income taxes and equity in losses of investee $ 100,545 $ 63,318 Geographical Information Net revenues are presented below by geographic area (in thousands): Three Months Ended 2018 2017 Net revenues 1 : United States $ 237,103 $ 183,273 The Netherlands 139,531 99,799 Other International 60,290 27,269 Total net revenues $ 436,924 $ 310,341 1 Net revenues are attributed to countries based on location of where revenue is recognized. Tangible long-lived assets are presented below by geographic area (in thousands): March 31, December 31, 2017 Long-lived assets 1 : The Netherlands $ 164,165 $ 143,673 United States 126,983 128,171 Costa Rica 48,470 30,738 Mexico 30,215 25,090 China 12,258 5,480 Other International 18,437 15,641 Total long-lived assets $ 400,528 $ 348,793 1 Long-lived assets are attributed to countries based on entity that owns the assets. |
Summary of Significant Accoun30
Summary of Significant Accounting Policies - Narrative (Details) $ in Millions | Mar. 31, 2018USD ($) |
Notes To Financial Statements [Abstract] | |
Revenue remaining performance obligation | $ 309 |
Summary of Significant Accoun31
Summary of Significant Accounting Policies - Balance sheet as adjusted (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Accounts receivable, net | $ 361,459 | $ 324,189 |
Deferred tax assets | 45,524 | 49,334 |
Other assets | 43,893 | |
Accrued liabilities | 180,093 | 195,562 |
Deferred revenues | 296,011 | 267,713 |
Retained earnings | $ 267,336 | 267,274 |
As Previously Reported | Accounting Standards Update 2014-09 | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Accounts receivable, net | 322,825 | |
Deferred tax assets | 50,059 | |
Other assets | 38,379 | |
Accrued liabilities | 194,198 | |
Deferred revenues | 266,842 | |
Retained earnings | 263,356 | |
Adjustment | Accounting Standards Update 2014-09 | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Accounts receivable, net | 1,364 | |
Deferred tax assets | (725) | |
Other assets | 5,514 | |
Accrued liabilities | 1,364 | |
Deferred revenues | 871 | |
Retained earnings | $ 3,918 |
Summary of Significant Accoun32
Summary of Significant Accounting Policies - Cash flow statement as adjusted (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Initial Application Period [Line Items] | ||
Other investing activities | $ 462 | $ (850) |
Net cash provided by (used in) investing activities | 109,269 | (148,462) |
Net increase (decrease) in cash, cash equivalent, and restricted cash | (131,412) | |
Cash, cash equivalents, and restricted cash at beginning of the period | 450,125 | 393,019 |
Cash, cash equivalents, and restricted cash at end of the period | $ 498,619 | 261,607 |
As Previously Reported | ||
Initial Application Period [Line Items] | ||
Other investing activities | 2,314 | |
Net cash provided by (used in) investing activities | (145,298) | |
Net increase (decrease) in cash, cash equivalent, and restricted cash | (128,248) | |
Cash, cash equivalents, and restricted cash at beginning of the period | 389,275 | |
Cash, cash equivalents, and restricted cash at end of the period | 261,027 | |
Accounting Standards Update 2016-18 | Adjustment | ||
Initial Application Period [Line Items] | ||
Other investing activities | (3,164) | |
Net cash provided by (used in) investing activities | (3,164) | |
Net increase (decrease) in cash, cash equivalent, and restricted cash | (3,164) | |
Cash, cash equivalents, and restricted cash at beginning of the period | 3,744 | |
Cash, cash equivalents, and restricted cash at end of the period | $ 580 |
Short-Term and Long-Term Market
Short-Term and Long-Term Marketable Securities (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Schedule of Available-for-sale Securities [Line Items] | ||
Total available for sale short-term and long-term marketable securities | $ 174,952 | $ 311,979 |
Fair Value, Measurements, Recurring | Short-term Investments | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Amortized Cost | 165,176 | 272,280 |
Gross Unrealized Gains | 1 | 3 |
Gross Unrealized Losses | (437) | (252) |
Total available for sale short-term and long-term marketable securities | 164,740 | 272,031 |
Fair Value, Measurements, Recurring | Short-term Investments | Commercial paper | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Amortized Cost | 20,447 | 58,503 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | (1) | (1) |
Total available for sale short-term and long-term marketable securities | 20,446 | 58,502 |
Fair Value, Measurements, Recurring | Short-term Investments | Corporate bonds | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Amortized Cost | 106,583 | 145,728 |
Gross Unrealized Gains | 1 | 3 |
Gross Unrealized Losses | (333) | (174) |
Total available for sale short-term and long-term marketable securities | 106,251 | 145,557 |
Fair Value, Measurements, Recurring | Short-term Investments | U.S. government agency bonds | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Amortized Cost | 8,999 | 3,013 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | (52) | (7) |
Total available for sale short-term and long-term marketable securities | 8,947 | 3,006 |
Fair Value, Measurements, Recurring | Short-term Investments | U.S. government treasury bonds | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Amortized Cost | 28,146 | 60,650 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | (51) | (70) |
Total available for sale short-term and long-term marketable securities | 28,095 | 60,580 |
Fair Value, Measurements, Recurring | Short-term Investments | Certificates of deposit | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Amortized Cost | 1,001 | 4,386 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Total available for sale short-term and long-term marketable securities | 1,001 | 4,386 |
Fair Value, Measurements, Recurring | Long-term Investments | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Amortized Cost | 10,297 | 40,090 |
Gross Unrealized Gains | 1 | 2 |
Gross Unrealized Losses | (86) | (144) |
Total available for sale short-term and long-term marketable securities | 10,212 | 39,948 |
Fair Value, Measurements, Recurring | Long-term Investments | Corporate bonds | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Amortized Cost | 3,265 | 25,067 |
Gross Unrealized Gains | 1 | 2 |
Gross Unrealized Losses | (20) | (76) |
Total available for sale short-term and long-term marketable securities | 3,246 | 24,993 |
Fair Value, Measurements, Recurring | Long-term Investments | U.S. government agency bonds | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Amortized Cost | 7,032 | 15,023 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | (66) | (68) |
Total available for sale short-term and long-term marketable securities | $ 6,966 | $ 14,955 |
Marketable Securities and Fai34
Marketable Securities and Fair Value Measurements Additional Information (Details) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2018 | Dec. 31, 2017 | |
Schedule of Available-for-sale Securities [Line Items] | ||
Original maturity of highly liquid investments included in cash and cash equivalents | 40 months | |
Weighted average maturity | 5 months | 6 months |
Marketable Securities and Fai35
Marketable Securities and Fair Value Measurements Available For Sale Securities (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Investments, Debt and Equity Securities [Abstract] | ||
One year or less | $ 164,740 | $ 272,031 |
Due in greater than one year | 10,212 | 39,948 |
Total available for sale short-term and long-term marketable securities | $ 174,952 | $ 311,979 |
Marketable Securities and Fai36
Marketable Securities and Fair Value Measurements - Reconciliation (Details) $ in Thousands | 3 Months Ended |
Mar. 31, 2018USD ($) | |
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | |
Balance as of December 31, 2017 | $ 4,476 |
Accrued interest receivable | 25 |
Change in fair value recognized in earnings | 358 |
Balance as of March 31, 2018 | $ 4,859 |
Summary of Financial Assets Mea
Summary of Financial Assets Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | $ 174,952 | $ 311,979 |
Fair Value, Measurements, Recurring | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Assets, Fair Value Disclosure | 438,298 | 581,947 |
Fair Value, Measurements, Recurring | Prepaid expenses and other current assets | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Other assets | 3,114 | 3,075 |
Fair Value, Measurements, Recurring | Short-term notes receivable | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Short-term notes receivable | 4,859 | 4,476 |
Fair Value, Measurements, Recurring | Cash Equivalents | Money market funds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Cash equivalents | 255,373 | 253,155 |
Fair Value, Measurements, Recurring | Cash Equivalents | Commercial paper | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Cash equivalents | 7,246 | |
Fair Value, Measurements, Recurring | Cash Equivalents | Corporate bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Cash equivalents | 2,016 | |
Fair Value, Measurements, Recurring | Short-term Investments | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 164,740 | 272,031 |
Fair Value, Measurements, Recurring | Short-term Investments | Commercial paper | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 20,446 | 58,502 |
Fair Value, Measurements, Recurring | Short-term Investments | Corporate bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 106,251 | 145,557 |
Fair Value, Measurements, Recurring | Short-term Investments | U.S. government agency bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 8,947 | 3,006 |
Fair Value, Measurements, Recurring | Short-term Investments | U.S. government treasury bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 28,095 | 60,580 |
Fair Value, Measurements, Recurring | Short-term Investments | Certificates of deposit | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 1,001 | 4,386 |
Fair Value, Measurements, Recurring | Long-term Investments | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 10,212 | 39,948 |
Fair Value, Measurements, Recurring | Long-term Investments | Corporate bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 3,246 | 24,993 |
Fair Value, Measurements, Recurring | Long-term Investments | U.S. government agency bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 6,966 | 14,955 |
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Assets, Fair Value Disclosure | 283,468 | 313,735 |
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Prepaid expenses and other current assets | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Other assets | 0 | 0 |
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term notes receivable | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Short-term notes receivable | 0 | 0 |
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash Equivalents | Money market funds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Cash equivalents | 255,373 | 253,155 |
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash Equivalents | Commercial paper | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Cash equivalents | 0 | |
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash Equivalents | Corporate bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Cash equivalents | 0 | |
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term Investments | Commercial paper | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 0 | 0 |
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term Investments | Corporate bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 0 | 0 |
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term Investments | U.S. government agency bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 0 | 0 |
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term Investments | U.S. government treasury bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 28,095 | 60,580 |
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term Investments | Certificates of deposit | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 0 | 0 |
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term Investments | Corporate bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 0 | 0 |
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term Investments | U.S. government agency bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 0 | 0 |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Assets, Fair Value Disclosure | 149,971 | 263,736 |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Prepaid expenses and other current assets | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Other assets | 3,114 | 3,075 |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Short-term notes receivable | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Short-term notes receivable | 0 | 0 |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Cash Equivalents | Money market funds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Cash equivalents | 0 | 0 |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Cash Equivalents | Commercial paper | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Cash equivalents | 7,246 | |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Cash Equivalents | Corporate bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Cash equivalents | 2,016 | |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Short-term Investments | Commercial paper | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 20,446 | 58,502 |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Short-term Investments | Corporate bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 106,251 | 145,557 |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Short-term Investments | U.S. government agency bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 8,947 | 3,006 |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Short-term Investments | U.S. government treasury bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 0 | 0 |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Short-term Investments | Certificates of deposit | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 1,001 | 4,386 |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Long-term Investments | Corporate bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 3,246 | 24,993 |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Long-term Investments | U.S. government agency bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 6,966 | 14,955 |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 3) | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Assets, Fair Value Disclosure | 4,859 | 4,476 |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 3) | Prepaid expenses and other current assets | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Other assets | 0 | 0 |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 3) | Short-term notes receivable | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Short-term notes receivable | 4,859 | 4,476 |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 3) | Cash Equivalents | Money market funds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Cash equivalents | 0 | 0 |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 3) | Cash Equivalents | Commercial paper | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Cash equivalents | 0 | |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 3) | Cash Equivalents | Corporate bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Cash equivalents | 0 | |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 3) | Short-term Investments | Commercial paper | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 0 | 0 |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 3) | Short-term Investments | Corporate bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 0 | 0 |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 3) | Short-term Investments | U.S. government agency bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 0 | 0 |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 3) | Short-term Investments | U.S. government treasury bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 0 | 0 |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 3) | Short-term Investments | Certificates of deposit | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 0 | 0 |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 3) | Long-term Investments | Corporate bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | 0 | 0 |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 3) | Long-term Investments | U.S. government agency bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ||
Investments | $ 0 | $ 0 |
Marketable Securities and Fai38
Marketable Securities and Fair Value Measurements - Derivative Notional Instruments (Details) - Mar. 31, 2018 - Significant Other Observable Inputs (Level 2) - Prepaid expenses and other current assets - Foreign Exchange Forward € in Thousands, £ in Thousands, $ in Thousands | EUR (€) | USD ($) | GBP (£) |
Derivative [Line Items] | |||
Notional amount | $ 61,859 | ||
Euro | |||
Derivative [Line Items] | |||
Notional amount | € 40,000 | 49,244 | |
British Pound | |||
Derivative [Line Items] | |||
Notional amount | $ 12,615 | £ 9,000 |
Inventories (Details)
Inventories (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Disclosure Inventories [Abstract] | ||
Raw materials | $ 13,386 | $ 12,721 |
Work in process | 11,442 | 12,157 |
Finished goods | 11,038 | 6,810 |
Total inventories | $ 35,866 | $ 31,688 |
Balance Sheet Components Other
Balance Sheet Components Other Assets (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Notes To Financial Statements [Abstract] | ||
Capitalized commissions | $ 7,681 | $ 5,515 |
Other long-term assets | 5,831 | 4,821 |
Security deposits | 3,721 | 3,557 |
Loan receivable | 0 | 30,000 |
Total other assets | $ 17,233 | $ 43,893 |
Accrued Liabilities (Details)
Accrued Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Disclosure Accrued Liabilities [Abstract] | ||
Accrued payroll and benefits | $ 69,581 | $ 103,004 |
Accrued expenses | 32,458 | 27,318 |
Accrued income taxes | 17,134 | 12,405 |
Accrued fixed assets | 15,241 | 11,362 |
Accrued warranty | 6,657 | 5,929 |
Accrued professional fees | 6,562 | 6,316 |
Accrued sales tax and value added tax | 5,340 | 5,503 |
Accrued sales rebate | 5,121 | 11,209 |
Accrued sales return reserve | 4,887 | 1,364 |
Other accrued liabilities | 17,112 | 11,152 |
Total accrued liabilities | $ 180,093 | $ 195,562 |
Warranty Accrual Activity (Deta
Warranty Accrual Activity (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Movement in Standard Product Warranty Accrual [Roll Forward] | ||
Balance at beginning of period | $ 5,929 | $ 3,841 |
Charged to cost of revenues | 2,359 | 1,822 |
Actual warranty expenditures | (1,631) | (1,362) |
Balance at end of period | $ 6,657 | $ 4,301 |
Balance Sheet Components Deferr
Balance Sheet Components Deferred Revenues (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Notes To Financial Statements [Abstract] | ||
Deferred revenues - current | $ 296,011 | $ 267,713 |
Deferred revenues - long-term | $ 6,171 | $ 4,588 |
Balance Sheet Components - Narr
Balance Sheet Components - Narrative (Details) - USD ($) $ in Thousands | 3 Months Ended | |||
Mar. 31, 2018 | Dec. 31, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | |
Condensed Balance Sheet Statements, Captions [Line Items] | ||||
Deferred revenues | $ 436,924 | $ 310,341 | ||
Deferred Revenue | ||||
Condensed Balance Sheet Statements, Captions [Line Items] | ||||
Deferred revenues | $ 86,000 | $ 51,000 |
Equity Method Investments (Deta
Equity Method Investments (Details) - USD ($) $ in Thousands | Jul. 24, 2017 | Jul. 25, 2016 | Mar. 31, 2018 | Mar. 31, 2017 | Feb. 07, 2018 | Dec. 31, 2017 |
Schedule of Equity Method Investments [Line Items] | ||||||
Equity method investments | $ 52,829 | $ 54,606 | ||||
Net revenues | 436,924 | $ 310,341 | ||||
SDC | ||||||
Schedule of Equity Method Investments [Line Items] | ||||||
Ownership | 19.00% | 17.00% | ||||
Payments to acquire | $ 12,800 | $ 46,700 | ||||
Additional ownership acquired | 2.00% | |||||
Due from related parties | 8,100 | $ 14,300 | ||||
Net revenues | $ 5,300 | $ 600 | ||||
Loan receivable | $ 30,000 | $ 30,000 |
Business Combinations (Details)
Business Combinations (Details) - Certain Distributors $ in Millions | 3 Months Ended |
Mar. 31, 2017USD ($) | |
Business Acquisition [Line Items] | |
Cash consideration | $ 9.5 |
Net tangible liabilities | 1.9 |
Intangibles acquired | 8.2 |
Goodwill and intangible assets, net | $ 3.2 |
Goodwill and Intangible Asset47
Goodwill and Intangible Assets - Change in Carrying Value of Goodwill (Details) - Clear Aligner $ in Thousands | 3 Months Ended |
Mar. 31, 2018USD ($) | |
Goodwill [Roll Forward] | |
Balance as of December 31, 2017 | $ 64,614 |
Adjustments | 7 |
Balance as of March 31, 2018 | $ 64,621 |
Goodwill and Intangible Asset48
Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2018 | Dec. 31, 2017 | |
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount, beginning balance | $ 68,114 | $ 68,116 |
Accumulated Amortization | (25,848) | (24,404) |
Accumulated Impairment Loss | (19,258) | (19,258) |
Net Carrying Value, ending balance | $ 23,008 | $ 24,454 |
Trademarks | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted Average Amortization Period (in years) | 15 years | 15 years |
Gross Carrying Amount, beginning balance | $ 7,100 | $ 7,100 |
Accumulated Amortization | (1,803) | (1,769) |
Accumulated Impairment Loss | (4,179) | (4,179) |
Net Carrying Value, ending balance | $ 1,118 | $ 1,152 |
Existing technology | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted Average Amortization Period (in years) | 13 years | 13 years |
Gross Carrying Amount, beginning balance | $ 12,600 | $ 12,600 |
Accumulated Amortization | (4,845) | (4,704) |
Accumulated Impairment Loss | (4,328) | (4,328) |
Net Carrying Value, ending balance | $ 3,427 | $ 3,568 |
Customer relationships | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted Average Amortization Period (in years) | 11 years | 11 years |
Gross Carrying Amount, beginning balance | $ 33,500 | $ 33,500 |
Accumulated Amortization | (15,147) | (14,681) |
Accumulated Impairment Loss | (10,751) | (10,751) |
Net Carrying Value, ending balance | $ 7,602 | $ 8,068 |
Reacquired rights | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted Average Amortization Period (in years) | 3 years | 3 years |
Gross Carrying Amount, beginning balance | $ 7,500 | $ 7,500 |
Accumulated Amortization | (1,914) | (1,356) |
Accumulated Impairment Loss | 0 | 0 |
Net Carrying Value, ending balance | $ 5,586 | $ 6,144 |
Patents | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted Average Amortization Period (in years) | 8 years | 8 years |
Gross Carrying Amount, beginning balance | $ 6,796 | $ 6,798 |
Accumulated Amortization | (1,712) | (1,504) |
Accumulated Impairment Loss | 0 | 0 |
Net Carrying Value, ending balance | $ 5,084 | $ 5,294 |
Other | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted Average Amortization Period (in years) | 2 years | 2 years |
Gross Carrying Amount, beginning balance | $ 618 | $ 618 |
Accumulated Amortization | (427) | (390) |
Accumulated Impairment Loss | 0 | 0 |
Net Carrying Value, ending balance | $ 191 | $ 228 |
Goodwill and Intangible Asset49
Goodwill and Intangible Assets - Total Estimated Annual Future Amortization Expense for Acquired Intangible Assets (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Disclosure Total Estimated Annual Future Amortization Expense For Acquired Intangible Assets [Abstract] | ||
Remainder of 2018 | $ 4,843 | |
2,019 | 6,343 | |
2,020 | 3,882 | |
2,021 | 3,389 | |
2,022 | 2,116 | |
Thereafter | 2,435 | |
Net Carrying Value, ending balance | $ 23,008 | $ 24,454 |
Goodwill and Intangible Asset50
Goodwill and Intangible Assets - Narrative (Details) - USD ($) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | Dec. 31, 2016 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |||
Goodwill impairment | $ 0 | ||
Amortization | $ 1,400,000 | $ 1,400,000 |
Credit Facilities - Additional
Credit Facilities - Additional Information (Details) - USD ($) | Feb. 27, 2018 | Mar. 31, 2018 | Mar. 22, 2013 |
Line of Credit Facility [Line Items] | |||
Line of credit, available borrowings | $ 200,000,000 | $ 50,000,000 | |
Current borrowing capacity | $ 50,000,000 | $ 10,000,000 | |
Outstanding borrowings | $ 0 | ||
Base Rate | |||
Line of Credit Facility [Line Items] | |||
Basis Spread on Variable Rate | 0.50% | ||
London Interbank Offered Rate (LIBOR) | |||
Line of Credit Facility [Line Items] | |||
Basis Spread on Variable Rate | 1.00% | ||
Minimum | Base Rate | |||
Line of Credit Facility [Line Items] | |||
Basis Spread on Variable Rate | 0.25% | ||
Minimum | London Interbank Offered Rate (LIBOR) | |||
Line of Credit Facility [Line Items] | |||
Basis Spread on Variable Rate | 1.25% | ||
Maximum | Base Rate | |||
Line of Credit Facility [Line Items] | |||
Basis Spread on Variable Rate | 0.75% | ||
Maximum | London Interbank Offered Rate (LIBOR) | |||
Line of Credit Facility [Line Items] | |||
Basis Spread on Variable Rate | 1.75% |
Legal Proceedings - Narrative (
Legal Proceedings - Narrative (Details) | Nov. 14, 2017Lawsuitpatent |
Lawsuit Against 3Shape AS | |
Loss Contingencies [Line Items] | |
Number of lawsuits/complaints | 6 |
Patents Allegedly Infringed upon | patent | 26 |
Violation Of Trade Laws 3Shape | |
Loss Contingencies [Line Items] | |
Number of lawsuits/complaints | 2 |
Patent Infringement By 3Shape | |
Loss Contingencies [Line Items] | |
Number of lawsuits/complaints | 4 |
Commitments and Contingencies M
Commitments and Contingencies Minimum Future Lease Payments for Non-Cancelable Leases (Details) - USD ($) | Jul. 25, 2016 | Mar. 31, 2018 |
Disclosure Minimum Future Lease Payments For Non Cancelable Leases [Abstract] | ||
Remainder of 2018 | $ 13,508,000 | |
2,019 | 15,061,000 | |
2,020 | 11,056,000 | |
2,021 | 9,270,000 | |
2,022 | 7,107,000 | |
Thereafter | 10,537,000 | |
Total minimum lease payments | $ 66,539,000 | |
Maximum | SDC | ||
Other Commitments [Line Items] | ||
Loan facility | $ 30,000,000 |
Stockholders' Equity - Addition
Stockholders' Equity - Additional Information (Details) $ in Millions | 3 Months Ended |
Mar. 31, 2018USD ($)shares | |
Incentive Plan 2005 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Shares reserved for issuance | 27,783,379 |
Number of shares available for issuance | 6,302,917 |
Employee Stock Purchase Plan 2010 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Maximum number of shares available | 2,400,000 |
Number of shares remaining | 647,363 |
Restricted Stock Units (RSUs) | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Total unamortized compensation cost | $ | $ 105.2 |
Weighted average period of total unamortized cost (in years) | 2 years 6 months |
Market Performance Based Restricted Stock Units | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Total unamortized compensation cost | $ | $ 28.6 |
Weighted average period of total unamortized cost (in years) | 1 year 3 months |
Market Performance Based Restricted Stock Units | Minimum | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Vesting period of granted market-performance based restricted stock units | 2 years |
Market Performance Based Restricted Stock Units | Maximum | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Vesting period of granted market-performance based restricted stock units | 3 years |
Percentage of market-performance based restricted stock units eligible to vest over the vesting period | 250.00% |
Employee Stock Purchase Plan | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Total unamortized compensation cost | $ | $ 2.4 |
Weighted average period of total unamortized cost (in years) | 8 months |
Stockholders' Equity - Stock-Ba
Stockholders' Equity - Stock-Based Compensation Expense Related to All Stock-Based Awards and Employee Stock Purchases (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Stock-based compensation expense | $ 15,830 | $ 14,812 |
Cost of net revenues | ||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Stock-based compensation expense | 881 | 925 |
Selling, general and administrative | ||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Stock-based compensation expense | 12,578 | 11,716 |
Research and development | ||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Stock-based compensation expense | $ 2,371 | $ 2,171 |
Stockholders' Equity - Activity
Stockholders' Equity - Activity Under Stock Option Plans (Details) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended |
Mar. 31, 2018USD ($)$ / sharesshares | |
Number of Shares Underlying Stock Options | |
Outstanding as of December 31, 2017 | shares | 75 |
Exercised | shares | (15) |
Cancelled or expired | shares | 0 |
Outstanding as of March 31, 2018 | shares | 60 |
Vested at March 31, 2018 | shares | 60 |
Exercisable at March 31, 2018 | shares | 60 |
Weighted Average Exercise Price per Share | |
Outstanding as of December 31, 2017 | $ / shares | $ 11.36 |
Exercised | $ / shares | 11.65 |
Cancelled or expired | $ / shares | 0 |
Outstanding as of March 31, 2018 | $ / shares | 11.28 |
Vested at March 31, 2018 | $ / shares | 11.28 |
Exercisable at March 31, 2018 | $ / shares | $ 11.28 |
Weighted Average Remaining Contractual Term | |
Outstanding as of March 31, 2018 | 9 months 22 days |
Vested at March 31, 2018 | 9 months 22 days |
Exercisable at March 31, 2018 | 9 months 22 days |
Aggregate Intrinsic Value | |
Outstanding as of March 31, 2018 | $ | $ 14,369 |
Vested at March 31, 2018 | $ | 14,369 |
Exercisable at March 31, 2018 | $ | $ 14,369 |
Stockholders' Equity - Summary
Stockholders' Equity - Summary of Nonvested Shares (Details) - Restricted Stock Units (RSUs) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended |
Mar. 31, 2018USD ($)$ / sharesshares | |
Number of Shares Underlying RSUs | |
Nonvested as of December 31, 2017 | shares | 1,341 |
Granted | shares | 193 |
Vested and released | shares | (439) |
Forfeited | shares | (39) |
Nonvested as of March 31, 2018 | shares | 1,056 |
Weighted Average Grant Date Fair Value | |
Nonvested as of December 31, 2017 | $ / shares | $ 82.30 |
Granted | $ / shares | 254.22 |
Vested and released | $ / shares | 67.12 |
Forfeited | $ / shares | 103.23 |
Nonvested as of March 31, 2018 | $ / shares | $ 119.34 |
Weighted Remaining Contractual Term (in years) | |
Nonvested as of March 31, 2018 | 1 year 7 months 10 days |
Aggregate Intrinsic Value | |
Nonvested as of March 31, 2018 | $ | $ 265,087 |
Stockholders' Equity - Summar58
Stockholders' Equity - Summary of MSU Performance (Details) - Market Performance Based Restricted Stock Units $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended |
Mar. 31, 2018USD ($)$ / sharesshares | |
Number of Shares Underlying MSUs | |
Nonvested as of December 31, 2017 | shares | 428 |
Granted | shares | 110 |
Vested and released | shares | (146) |
Forfeited | shares | 0 |
Nonvested as of March 31, 2018 | shares | 392 |
Weighted Average Grant Date Fair Value | |
Nonvested as of December 31, 2017 | $ / shares | $ 78.53 |
Granted | $ / shares | 221.18 |
Vested and released | $ / shares | 56.75 |
Forfeited | $ / shares | 0 |
Nonvested as of March 31, 2018 | $ / shares | $ 126.58 |
Weighted Average Remaining Contractual Term (in years) | |
Nonvested as of March 31, 2018 | 1 year 3 months 7 days |
Aggregate Intrinsic Value | |
Nonvested as of March 31, 2018 | $ | $ 98,468 |
Stockholders' Equity - Stock-59
Stockholders' Equity - Stock-based Compensation Employee Stock Purchase Plan (Details) - $ / shares | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ||
Expected term (in years) | 1 year 3 months 18 days | 1 year 2 months 12 days |
Expected volatility | 35.70% | 26.10% |
Risk-free interest rate | 1.90% | 0.90% |
Expected dividends | 0.00% | 0.00% |
Weighted average fair value at grant date (USD per Share) | $ 78.38 | $ 26.09 |
Common Stock Repurchase - Addit
Common Stock Repurchase - Additional Information (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions | 1 Months Ended | |||||
Feb. 28, 2018 | Nov. 30, 2017 | May 31, 2017 | Jan. 31, 2017 | Mar. 31, 2018 | Apr. 28, 2016 | |
April 2014 Stock Repurchase Program | ||||||
Share Repurchases [Line Items] | ||||||
Accelerated share repurchase (shares) | 40 | |||||
Price ($ per share) | $ 96.37 | |||||
Repurchased | $ 3.8 | |||||
April 2016 Repurchase Program | ||||||
Share Repurchases [Line Items] | ||||||
Accelerated share repurchase (shares) | 400 | |||||
Price ($ per share) | $ 252.24 | |||||
Repurchased | $ 100 | |||||
Repurchase of common stock, common stock authorized | $ 300 | |||||
Amount remaining in repurchase plan | $ 100 | |||||
2017 ASR | ||||||
Share Repurchases [Line Items] | ||||||
Accelerated share repurchase (shares) | 200 | 400 | ||||
Price ($ per share) | $ 243.40 | $ 146.48 | ||||
Repurchased | $ 50 | $ 50 |
Accounting for Income Taxes - A
Accounting for Income Taxes - Additional Information (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | ||
Mar. 31, 2018 | Dec. 31, 2017 | Mar. 31, 2017 | Dec. 31, 2017 | |
Income Taxes [Line Items] | ||||
Provision for (benefit from) income taxes | $ 2,902 | $ (7,223) | ||
Effective income tax rate, continuing operations | 2.90% | (11.40%) | ||
Statutory federal income tax rate | 35.00% | |||
Unrecognized tax benefits | $ 50,300 | $ 47,700 | $ 47,700 | |
Accrued penalties and interest | 3,300 | |||
Unrecognized tax benefits that would impact effective tax rate | 28,000 | |||
Undistributed earnings of foreign subsidiaries | 606,500 | 606,500 | ||
Amount of no longer indefinitely reinvested foreign earnings | 591,900 | |||
Deferred tax liability due in event of foreign earnings being distributed | 3,300 | |||
Amount of indefinitely reinvested foreign earnings | 14,700 | $ 14,700 | ||
Additional income tax expense due to TCJA | $ 2,400 | $ 84,300 | ||
Foreign Tax Authority | ||||
Income Taxes [Line Items] | ||||
Foreign income tax rate | 30.00% | 30.00% | ||
Accounting Standards Update 2016-09 | ||||
Income Taxes [Line Items] | ||||
Tax benefit | $ 23,300 | $ 21,300 |
Computation of Basic and Dilute
Computation of Basic and Diluted Net Income Per Share Attributable to Common Stock (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Earnings Per Share [Abstract] | ||
Net income | $ 95,866 | $ 69,420 |
Weighted-average common shares outstanding, basic | 80,036 | 79,904 |
Dilutive effect of potential common stock | 1,592 | 1,630 |
Total shares, diluted | 81,628 | 81,534 |
Net income per share, basic | $ 1.20 | $ 0.87 |
Net income per share, diluted | $ 1.17 | $ 0.85 |
Segments and Geographical Inf63
Segments and Geographical Information - Additional Information (Details) | 3 Months Ended |
Mar. 31, 2018segment | |
Disclosure Segments And Geographical Information Additional Information [Abstract] | |
Number of reportable segments | 2 |
Segments and Geographical Inf64
Segments and Geographical Information - Segment Information (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Segment Reporting Information [Line Items] | ||
Net revenues | $ 436,924 | $ 310,341 |
Gross profit | 327,408 | 235,625 |
Income from operations | 98,192 | 61,673 |
Interest income | 2,176 | 1,195 |
Depreciation and amortization | 11,434 | 7,867 |
Other income (expense), net | 177 | 450 |
Net income before provision for (benefit from) income taxes and equity in losses of investee | 100,545 | 63,318 |
Operating segments | ||
Segment Reporting Information [Line Items] | ||
Income from operations | 177,536 | 120,738 |
Clear Aligner | ||
Segment Reporting Information [Line Items] | ||
Net revenues | 385,505 | 282,399 |
Gross profit | 296,976 | 219,947 |
Income from operations | 161,454 | 114,734 |
Depreciation and amortization | 6,384 | 4,363 |
Scanner | ||
Segment Reporting Information [Line Items] | ||
Net revenues | 51,419 | 27,942 |
Gross profit | 30,432 | 15,678 |
Income from operations | 16,082 | 6,004 |
Depreciation and amortization | 1,104 | 1,037 |
Unallocated corporate expenses | ||
Segment Reporting Information [Line Items] | ||
Income from operations | (79,344) | (59,065) |
Depreciation and amortization | $ 3,946 | $ 2,467 |
Segments and Geographical Inf65
Segments and Geographical Information - Net Revenues by Geographic Area (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Segment Reporting Information [Line Items] | ||
Net revenues | $ 436,924 | $ 310,341 |
United States | ||
Segment Reporting Information [Line Items] | ||
Net revenues | 237,103 | 183,273 |
The Netherlands | ||
Segment Reporting Information [Line Items] | ||
Net revenues | 139,531 | 99,799 |
Other International | ||
Segment Reporting Information [Line Items] | ||
Net revenues | $ 60,290 | $ 27,269 |
Segments and Geographical Inf66
Segments and Geographical Information - Long-Lived Assets by Geographic Area (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Dec. 31, 2017 |
Segment Reporting Information [Line Items] | ||
Long-lived assets | $ 400,528 | $ 348,793 |
The Netherlands | ||
Segment Reporting Information [Line Items] | ||
Long-lived assets | 164,165 | 143,673 |
United States | ||
Segment Reporting Information [Line Items] | ||
Long-lived assets | 126,983 | 128,171 |
Costa Rica | ||
Segment Reporting Information [Line Items] | ||
Long-lived assets | 48,470 | 30,738 |
Mexico | ||
Segment Reporting Information [Line Items] | ||
Long-lived assets | 30,215 | 25,090 |
China | ||
Segment Reporting Information [Line Items] | ||
Long-lived assets | 12,258 | 5,480 |
Other International | ||
Segment Reporting Information [Line Items] | ||
Long-lived assets | $ 18,437 | $ 15,641 |